A second agent of a coating-type body correction film-forming agent comprising a first agent and a second agent, and a lubricating layer-forming agent applied to a body correction film.

Abstract

The present invention provides a second agent for a body corrective film-forming agent that can protect the formed body corrective film from external stimuli, and a lubricating layer-forming agent that can be applied to the body corrective film. [Solution] In a coating-type body correcting film-forming agent, the second agent of the present disclosure is used, comprising a first agent containing a crosslinking reactive component that constitutes a body correcting film and a second agent containing a crosslinking component that crosslinks the crosslinking reactive component. The second agent of the present disclosure includes a catalyst as a crosslinking component and a lubricating component, and the lubricating layer-forming agent applied to the body correcting film of the present disclosure includes a lubricating component.

Description

[Technical Field]

[0001] This disclosure relates to a second agent of a coating-type body corrective coating agent comprising a first agent and a second agent, and to a lubricating layer-forming agent applied to a body corrective coating. [Background technology]

[0002] There are known topical film-forming agents that can be applied to the body surface to form a film capable of correcting wrinkles, scars, and other imperfections.

[0003] Patent Document 1 discloses a formulation for application to the skin, comprising: a) (i) a reactive element comprising at least one high-viscosity vinyl-terminated organopolysiloxane having a viscosity of 100,000 to 500,000 cst or cP at 25°C, at least one low-viscosity vinyl-terminated organopolysiloxane having a viscosity of 500 to 50,000 cst or cP at 25°C, and at least one hydride-functionalized polysiloxane; and (ii) a reactive reinforcing component comprising a reinforcing element; and b) a crosslinking component comprising a platinum catalyst; wherein the crosslinking component promotes the crosslinking of the reactive reinforcing component in situ, resulting in the formation of a film on the skin. [Prior art documents] [Patent Documents]

[0004] [Patent Document 1] Patent No. 6105468 [Overview of the project] [Problems that the invention aims to solve]

[0005] The technology described in Patent Document 1 is a technique in which a first agent containing reactive elements such as vinyl-terminated organopolysiloxane is applied to the skin to form a first agent layer, and then a second agent containing a platinum catalyst is applied to the first agent layer to crosslink the reactive elements in the first agent layer and form a film on the skin.

[0006] The coating formed by this technology may be subjected to physical stimuli, such as contact with the coating during use or the application of makeup on the coating, which could lead to defects such as tearing of the coating. Therefore, there was a need to protect the coating from such external stimuli.

[0007] Therefore, the subject of this disclosure is to provide a second agent for a body corrective film-forming agent that can protect the formed body corrective film from external stimuli, and a lubricating layer-forming agent that is applied to the body corrective film. [Means for solving the problem]

[0008] <Aspect 1> A second agent of a coating-type body corrective film-forming agent, comprising a first agent containing a crosslinking reactive component that constitutes a body corrective film, and a second agent containing a crosslinking component that crosslinks the crosslinking reactive component, The aforementioned crosslinking component includes a catalyst and a lubricating component. Second drug. <Aspect 2> The second agent according to Embodiment 1, wherein the lubricating component is at least one selected from the group consisting of a humectant having a sugar skeleton, an oil having a sugar skeleton, a film-forming agent, a water-soluble polymer, an emollient oil, and a silicone elastomer. <Aspect 3> The second agent according to embodiment 2, wherein the lubricating component includes a humectant having a sugar skeleton, and the amount of the humectant is 4.5% by mass or more. <Aspect 4> The second agent according to embodiment 2, wherein the lubricating component includes the coating agent, and the amount of the coating agent is 2.0% by mass or more. <Aspect 5> The second agent according to embodiment 2, wherein the lubricating component includes the water-soluble polymer, and the amount of the water-soluble polymer is 0.05% by mass or more. <Pattern 6> The second agent according to any one of embodiments 1 to 5, which is a single-phase system composed of an oil phase, a two-phase system composed of an oil-in-water emulsion composition or a water-in-oil emulsion composition, or a non-emulsified two-phase system. <Aspect 7> The second agent according to any one of embodiments 1 to 6, wherein the catalyst is at least one selected from the group consisting of platinum carbonylcyclovinylmethylsiloxane complex, platinum divinyltetramethyldisiloxane complex, platinum cyclovinylmethylsiloxane complex, and platinum octanealdehyde / octanol complex. <Aspect 8> A topical body corrective film-forming agent comprising a first agent and a second agent, The first agent comprises at least one selected from the group consisting of a first unsaturated organopolysiloxane and a first hydride-functionalized polysiloxane. The aforementioned second agent is the second agent described in any of embodiments 1 to 7, If the first agent comprises only the first unsaturated organopolysiloxane among the first unsaturated organopolysiloxane and the first hydride-functionalized polysiloxane, then the second agent comprises the second hydride-functionalized polysiloxane. If the first agent comprises only the first hydride-functionalized polysiloxane among the first unsaturated organopolysiloxane and the first hydride-functionalized polysiloxane, then the second agent comprises the second unsaturated organopolysiloxane. A topical body correction film-forming agent. <Aspect 9> The forming agent according to embodiment 8, wherein the first unsaturated organopolysiloxane and the second unsaturated organopolysiloxane are at least one selected from the group consisting of organopolysiloxanes having vinyl groups, vinyl-terminated organopolysiloxanes, and organopolysiloxanes having vinyl-terminated branched chains. <Aspect 10> The shaping agent according to embodiment 9, wherein the first unsaturated organopolysiloxane and the second unsaturated organopolysiloxane are at least one selected from the group consisting of vinyl-terminated polydimethylsiloxane, vinyl-terminated diphenylsiloxane-dimethylsiloxane copolymer, vinyl-terminated polyphenylmethylsiloxane, vinylphenylmethyl-terminated vinylphenylsiloxane-phenylmethylsiloxane copolymer, vinyl-terminated trifluoropropylmethylsiloxane-dimethylsiloxane copolymer, vinyl-terminated diethylsiloxane-dimethylsiloxane copolymer, vinyl-methylsiloxane-dimethylsiloxane copolymer, trimethylsiloxy-terminated vinylmethylsiloxane-dimethylsiloxane copolymer, silanol-terminated vinylmethylsiloxane-dimethylsiloxane copolymer, vinyl methylsiloxane homopolymer, vinyl T-structure polymer, vinyl Q-structure polymer, monovinyl-terminated polydimethylsiloxane, vinyl methylsiloxane terpolymer, and vinyl methoxysilane homopolymer. <Aspect 11> The forming agent according to any one of embodiments 8 to 10, wherein the first hydride-functionalized polysiloxane and the second hydride-functionalized polysiloxane are non-terminal and / or terminally hydrogenated organopolysiloxanes. <Aspect 12> The forming agent according to embodiment 11, wherein the first hydride-functionalized polysiloxane and the second hydride-functionalized polysiloxane are at least one selected from the group consisting of hydride-terminated polydimethylsiloxane, hydride-terminated polyphenyl-(dimethylhydrosiloxy)siloxane, hydride-terminated methylhydrosiloxane-phenylmethylsiloxane copolymer, trimethylsiloxy-terminated methylhydrosiloxane-dimethylsiloxane copolymer, polymethylhydrosiloxane, trimethylsiloxy-terminated polyethylhydrosiloxane, triethylsiloxane, methylhydrosiloxane-phenyloctylmethylsiloxane copolymer, and methylhydrosiloxane-phenyloctylmethylsiloxane terpolymer. <Aspect 13> The forming agent according to any one of embodiments 8 to 12, wherein at least one of the first agent and the second agent comprises at least one selected from the group consisting of fibers, pigments, dyes, thickeners, ultraviolet absorbers, and fillers. <Aspect 14> A kit in which the first agent and the second agent described in any of embodiments 8 to 13 are contained in separate containers, or are contained separately in each compartment of a container having two or more compartments. <Aspect 15> A method of using a forming agent as described in any of embodiments 8 to 13, After applying the first agent to the body surface to form a first agent layer, the second agent is applied on the first agent layer and crosslinked to form a body correction film. After applying the second agent to the body surface to form a second agent layer, the first agent is applied to the second agent layer and crosslinked to form a body correction film, or After mixing the first agent and the second agent to prepare a mixture, the mixture is applied to the body surface and crosslinked to form a body correction film. How to use. <Aspect 16> Before applying the first agent, the second agent, or the mixture to the body surface, apply a cosmetic to the body surface. The first agent is applied to the body surface to form a first agent layer, a cosmetic is applied on the first agent layer, and then the second agent is applied to cover the cosmetic. The second agent is applied to the body surface to form a second agent layer, a cosmetic is applied on the second agent layer, and then the first agent is applied to cover the cosmetic, or After forming a body correction film, a cosmetic is applied to the film. The method of use described in aspect 15. <Aspect 17> A lubricating layer-forming agent containing lubricating components, applied to body correction coatings. <Aspect 18> The agent according to embodiment 17, which is a single-phase system, a two-phase system composed in the form of an oil-in-water emulsion composition or a water-in-oil emulsion composition, or a non-emulsified two-phase system. <Aspect 19> A method for using a lubricating layer forming agent as described in embodiment 17 or 18, Applying a crosslinking reactive component constituting a body correction film and a crosslinking component that crosslinks the crosslinking reactive component to the body surface, crosslinking them to form a body correction film, and then applying the lubricating layer forming agent onto the film, or After forming the body correction film, a cosmetic is applied to the film, and then the lubricating layer forming agent is applied to cover the cosmetic. How to use. <Aspect 20> The method of use according to embodiment 19, wherein the lubricating layer forming agent is a cosmetic. <Aspect 21> The method of use according to any one of embodiments 16, 19, and 20, wherein the cosmetic is a skincare cosmetic, a sunscreen cosmetic, a base cosmetic, a makeup cosmetic, or a cosmetic that combines two or more of the functions of these cosmetics. [Effects of the Invention]

[0009] According to this disclosure, it is possible to provide a second agent for a coating-type body corrective film-forming agent that can protect the formed body corrective film from external stimuli, and a lubricating layer-forming agent that can be applied to a body corrective film. [Modes for carrying out the invention]

[0010] The embodiments of this disclosure will be described in detail below. This disclosure is not limited to the embodiments described below, and can be implemented in various ways within the scope of the essence of the invention.

[0011] In a coating-type body corrective film-forming agent, the second agent of the present disclosure, used in the application of the body corrective film-forming agent, comprises a first agent containing a crosslinking reactive component that constitutes a body corrective film and a second agent containing a crosslinking component that crosslinks the crosslinking reactive component, the second agent of the present disclosure comprises a catalyst as a crosslinking component and a lubricating component, and the lubricating layer-forming agent of the present disclosure applied to the body corrective film comprises a lubricating component.

[0012] Although not limited by principle, the following is considered to be the principle of action by which the second agent and lubricating layer-forming agent of this disclosure can protect the formed body correction film from external stimuli.

[0013] To form a body-correcting film (sometimes simply referred to as "film") using a two-part topical body-correcting film-forming agent, for example, the first agent containing a cross-linking reactive component is applied to the skin to form the first agent layer, and then the second agent containing a cross-linking component is applied to the first agent layer. By spreading the agent around, the cross-linking reactive component in the first agent layer is cross-linked, thereby forming a film on the skin.

[0014] The second agent of this disclosure contains a lubricating component in addition to the catalyst, which is a crosslinking component. We believe that this lubricating component bleeds out onto the film as the crosslinking reaction progresses. As a result, we believe that the lubricating component is positioned to cover the surface of the film and form a lubricating layer, thereby protecting the film from external stimuli. This is particularly noticeable when the lubricating component has poor compatibility with the crosslinked film component.

[0015] Furthermore, since the film during the crosslinking process is more brittle and prone to breakage than the film after crosslinking, there is a risk of damaging the film when applying the second agent to the first agent layer. However, the lubricating components contained in the second agent of this disclosure are thought to have the effect of reducing or suppressing damage to the film during the crosslinking process, and as a result, the second agent of this disclosure is thought to be able to protect the film from during film formation to after film formation.

[0016] On the other hand, a lubricating layer-forming agent containing lubricating components can be applied to the resulting body-correcting film to directly form a lubricating layer. As a result, we believe that the lubricating layer formed on the film can protect the film from external stimuli.

[0017] Furthermore, we believe that the lubricating layer formed by the lubricating layer-forming agent can contain a high concentration of lubricating components, thus providing a high level of protection for the coating.

[0018] The definitions of terms used in this disclosure are as follows:

[0019] In this disclosure, “body corrective coating” means a coating intended to exhibit a natural skin appearance when formed on the skin of a subject. Here, “natural skin appearance” means that, when applied to skin, the body corrective coating exhibits properties similar to or identical to at least one selected from the appearance, feel, and texture of actual skin, for example, that the coated skin may exhibit the physical properties (e.g., elasticity and hardness) of actual (e.g., current) skin.

[0020] In this disclosure, “body correction” means improving a body or skin defect visually and / or tactilely by masking, covering, or concealing a body or skin defect of a person, but does not include methods of surgery, treatment, or diagnosis of a person. Here, “body defect” can mean, for example, any part of the person’s body that the person perceives as a blemish or scar, or that a person skilled in the art, such as a dermatologist, esthetician, or orthopedic surgeon, would consider to be a blemish or scar. “Body defect” includes skin defects and looseness of the body’s soft tissues (e.g., loose or sagging skin, looseness of breasts, buttocks, abdomen, jaw, neck, etc.). “Skin defect” also includes any of these items on the person’s skin that the person perceives as a blemish or scar. Examples of skin defects include flame nevi or nevus (e.g., simple hemangioma or midline flame nevi), melasma, wrinkles, age spots, acne, moles, scars, tattoos, birthmarks, skin deformities, nevi, sunburn, aging, uneven skin tone, sagging skin, rough skin, hyperpigmentation, enlarged pores, tubular dilation, redness, oiliness, cellulite, stretch marks, or loss of skin elasticity.

[0021] In this disclosure, “viscosity” refers to a measure of the resistance of a fluid being deformed by either shear stress or tensile stress. For example, the viscosity of the first and second components in a coating-type body correction film-forming agent affects the thickness, ductility, and uniformity and / or homogeneity of the layer formed on the substrate. Viscosity can be expressed as dynamic viscosity (also known as absolute viscosity, typical units being Pa·s, poise, P, cP) or kinematic viscosity (typical units being cm). 2The viscosity can be reported as one of the following: / s, Stoke, St, or cst. This kinematic viscosity is the dynamic viscosity divided by the density of the measured fluid. The viscosity range of the components disclosed herein is generally provided by the supplier of each component as a unit of kinematic viscosity (e.g., cst) measured using a rheometer or Cannon-Fenske tube viscometer, although the viscosity of a fluid can also be measured using, for example, a rheometer (e.g., a linear shear rheometer or a dynamic shear rheometer) or a viscometer (a viscometer, also called a capillary viscometer or rotational viscometer).

[0022] In this disclosure, the term "crosslinking" also includes the concept commonly referred to as "hardening."

[0023] In this disclosure, "body surface" means the surface of the skin of the body.

[0024] 《Second component of a topical body correction film-forming agent containing the first and second components》 In a coating-type body corrective film-forming agent comprising a first agent containing a crosslinking reactive component that constitutes a body corrective film and a second agent containing a crosslinking component that crosslinks the crosslinking reactive component, the second agent of this disclosure includes a catalyst as a crosslinking component and a lubricating component, and can reduce or suppress damage to the obtained body corrective film due to external stimuli.

[0025] The second agent of this disclosure has the ability to protect the resulting film from external stimuli. This protective performance can be evaluated, for example, by the presence or absence of defects such as peeling or damage to the film 12 hours after formation. A film prepared using the second agent of this disclosure may, upon visual inspection, exhibit slight peeling and / or damage, or no peeling or damage at all.

[0026] The protective performance of the coating against external stimuli can also be evaluated by an abrasion resistance test described later. A coating prepared using the second agent of this disclosure can achieve a number of cycles before damage occurs in an abrasion resistance test of 5 or more, 7 or more, 10 or more, 12 or more, 15 or more, 17 or more, or 20 or more. There is no particular upper limit to such a number, but for example, it can be 200 or less, 150 or less, or 100 or less.

[0027] In some embodiments, the second agent of the present disclosure can improve the slipperiness and protective properties of the resulting film for cosmetics (e.g., foundation cosmetics). Such slipperiness and protective properties can be evaluated by the slipperiness and protective properties tests described later. Films prepared using the second agent of the present disclosure allow for uniform application of cosmetics without damaging the film during the slipperiness and protective properties tests.

[0028] <catalyst> There are no particular restrictions on the catalyst; for example, any substance capable of causing, promoting, or initiating physical and / or chemical crosslinking reactions with unsaturated organopolysiloxanes and hydride-functionalized polysiloxanes, which are crosslinking reactive components constituting the body correction film. The catalyst may or may not undergo permanent physical and / or chemical changes during or at the end of the process.

[0029] The catalysts are not limited to, but can be metal catalysts capable of initiating and / or promoting crosslinking at temperatures below body temperature, such as Group VIII metal catalysts, such as platinum catalysts, rhodium catalysts, palladium catalysts, cobalt catalysts, nickel catalysts, ruthenium catalysts, osmium catalysts, and iridium catalysts, and Group IVA metal catalysts, such as germanium catalysts and tin catalysts. Among these, platinum catalysts, rhodium catalysts, or tin catalysts are preferred. The catalysts can be used alone or in combination of two or more.

[0030] Examples of platinum catalysts include platinum carbonylcyclovinylmethylsiloxane complexes, platinum divinyltetramethyldisiloxane complexes, platinum cyclovinylmethylsiloxane complexes, platinum octanealdehyde / octanol complexes, and other Pt(0) catalysts such as Karlstedt catalysts, platinum-alcohol complexes, platinum-alkoxide complexes, platinum-ether complexes, platinum-aldehyde complexes, platinum-ketone complexes, platinum-halogen complexes, platinum-sulfur complexes, platinum-nitrogen complexes, platinum-phosphorus complexes, platinum-carbon double bond complexes, platinum-carbon triple bond complexes, platinum-imide complexes, platinum-amide complexes, platinum-ester complexes, platinum-phosphate ester complexes, platinum-thiol ester complexes, platinum lone pair complexes, platinum-aromatic complexes, platinum π-electron complexes, and combinations thereof. In particular, at least one selected from the group consisting of platinum carbonylcyclovinylmethylsiloxane complex, platinum divinyltetramethyldisiloxane complex, platinum cyclovinylmethylsiloxane complex, and platinum octanealdehyde / octanol complex is preferred.

[0031] Examples of rhodium catalysts include tris(dibutyl sulfide)rhodium trichloride and rhodium trichloride hydrate.

[0032] Examples of tin catalysts include tin(II) octanoate, tin(II) neodecanoate, dibutyltin diisooctylmaleate, di-n-butylbis(2,4-pentanedionate)tin, di-n-butylbutoxychlorotin, dibutyltin dilaurate, dimethyltin dineodecanoate, dimethylhydroxy(oleate)tin, and tin(II) oleate.

[0033] Among these catalysts, platinum catalysts are more preferred, and platinum divinyltetramethyldisiloxane complexes are particularly preferred.

[0034] The amount of catalyst in the second agent can be adjusted as appropriate according to the required coating performance, etc., and there are no particular restrictions. For example, the amount of catalyst can be 0.001% by mass or more, 0.005% by mass or more, or 0.010% by mass or more, or 1.0% by mass or less, 0.10% by mass or less, or 0.050% by mass or less, relative to the total amount of the second agent.

[0035] In some embodiments, the second agent of the present disclosure may, for example, when a platinum complex is used as a catalyst, have a mass ratio of unsaturated organopolysiloxane to the total amount of platinum in the platinum complex of less than 200.

[0036] <Lubricating component> The second agent of this disclosure contains a lubricating component. In this disclosure, "lubricating component" means a component that can form a lubricating layer on the film and can improve the protective performance of the film from external stimuli compared to a film without a lubricating layer. As for the lubricating component of the second agent, it is preferable that, for example, from the viewpoint of the protective performance of the film from external stimuli, the lubricating component bleeds out onto the film as the crosslinking reaction progresses. The lubricating component can be used alone or in combination of two or more types.

[0037] Examples of such lubricating components include humectants with a sugar skeleton, oils with a sugar skeleton, film-forming agents, water-soluble polymers, emollient oils, and silicone elastomers. Among these, humectants with a sugar skeleton and oils with a sugar skeleton are particularly suitable because they have poor compatibility with cross-linked film components and readily bleed out onto the film. In this disclosure, humectants with a sugar skeleton and oils with a sugar skeleton typically include compounds with a sugar skeleton. A "compound with a sugar skeleton" refers to a compound that has one >C=O or -CHO group and two or more -OH groups in its chemical structure; or a compound such as a sugar alcohol in which the >C=O group of such a compound has been reduced.

[0038] Examples of humectants with a sugar backbone include glycerin, sorbitol, mannitol, xylitol, trehalose, and PPG-20 methyl glucose.

[0039] Examples of oils containing a sugar backbone include PPG-20 methyl glucose distearate, polyoxyethylene sorbitan tetraoleate, sorbitan stearate, sorbitan sesquistearate, sucrose fatty acid esters, and glycerin fatty acid esters.

[0040] Examples of coating agents include polyurethane-based coating agents (e.g., polyurethane-10, polyurethane-35), polyvinylpyrrolidone-based coating agents (e.g., polyvinylpyrrolidone K30), and silicone-based coating agents (e.g., a mixture of tri(trimethylsiloxy)silylpropylcarbamate pullulan and cyclopentasiloxane).

[0041] Examples of water-soluble polymers include a mixture of PEG-240 / HDI copolymer bis-decyltetradeceth-20 ether and BHT, hydroxypropyl methylcellulose stearoxy ether, and succinoglycans. In addition, materials referred to as polymer emulsifiers can be used. Polymer emulsifiers typically have a larger molecular weight and lower emulsifying ability compared to general emulsifiers (surfactants).

[0042] The weight-average molecular weight of general emulsifiers (surfactants) other than high-molecular-weight emulsifiers can be less than 500, 450 or less, or 400 or less, and can also be 100 or more, 150 or more, or 200 or more.

[0043] The weight-average molecular weight of the polymer emulsifier can be 500 or more, 700 or more, 1,000 or more, 1,500 or more, or 2,000 or more. There is no particular upper limit on the weight-average molecular weight of the polymer emulsifier; for example, it can be 1,000,000 or less, 100,000 or less, 10,000 or less, or 5,000 or less.

[0044] The weight-average molecular weight of the emulsifier is the polystyrene equivalent value obtained by dissolving the emulsifier in N,N-dimethylformamide (DMF) to prepare a 0.5% solution, and then measuring it by GPC (gel permeation chromatography) under the following conditions: Two α-M columns (manufactured by Showa Denko Corporation) were connected in series and used. Eluent: DMF solution of 60 mmol / L H3PO4 and 50 mmol / L LiBr Flow rate: 1.0mL / min Column temperature: 40℃ Detector: RI Calibration curve: Created using polystyrene.

[0045] There are no particular restrictions on the polymer emulsifier, and examples include at least one selected from the group consisting of (acrylates / alkyl(C10-30)) crosspolymer, (ammonium acryloyldimethyltaurate / beheneth-25 methacrylate) crosspolymer, (hydroxyethyl acrylate / sodium acryloyldimethyltaurate) copolymer, PEG-modified crosspolymer / copolymer siloxane, polyether-modified crosspolymer / copolymer siloxane, stearoxyhydroxypropyl methylcellulose, and polyoxyethylene. Among these, (acrylates / alkyl(C10-30)) crosspolymer is preferred from the viewpoint of emulsification stability and storage stability of the platinum catalyst.

[0046] High molecular weight emulsifiers and other general emulsifiers (surfactants) can also be distinguished by their HLB (Heat Burden). The HLB of general emulsifiers (surfactants) can be 2.0 or higher, 3.0 or higher, or 4.0 or higher, and can also be 10.0 or lower, 9.0 or lower, or 8.0 or lower.

[0047] Examples of emollient oils include squalane, mineral oil, shea butter, hydrogenated polyisobutene, petrolatum, cetyl 2-ethylhexanoate, 2-octyldodecanol, di-2-ethylhexyl succinate, diisopropyl sebacate, avocado oil, olive oil, nut oil, palm oil, hydrogenated palm kernel oil, isononyl isononanoate, cetyl ethylhexanoate, oleyl alcohol, hydrogenated castor oil, and hydrogenated castor oil. Here, emollient oils do not include oils with a sugar backbone.

[0048] Examples of silicone elastomers include (dimethicone / vinyl dimethicone) crosspolymer, dimethicone crosspolymer, (dimethicone / bis-isobutyl PPG-20) crosspolymer, PPG-12 dimethicone / PPG-20 crosspolymer, dimethicone / PEG-10 / 15 crosspolymer, and polysilicone-11.

[0049] The amount of lubricating components in the second agent can be adjusted as appropriate according to the required protective performance of the coating, and there are no particular restrictions. For example, the amount of lubricating components can be 0.05% by mass or more, 0.10% by mass or more, 0.50% by mass or more, 1.0% by mass or more, 1.5% by mass or more, 2.0% by mass or more, 2.5% by mass or more, or 3.0% by mass or more, relative to the total amount of the second agent. There are no particular restrictions on the upper limit of the amount of lubricating components, and for example, it can be 50% by mass or less, 45% by mass or less, 40% by mass or less, 35% by mass or less, or 30% by mass or less.

[0050] Furthermore, when a humectant having the sugar skeleton described above is included as a lubricating component, the amount of such humectant is preferably 4.5% by mass or more, 4.7% by mass or more, 5.0% by mass or more, 5.3% by mass or more, 5.5% by mass or more, 5.7% by mass or more, or 6.0% by mass or more, relative to the total amount of the second agent, and also preferably 20% by mass or less, 15% by mass or less, or 10% by mass or less.

[0051] When the above-mentioned coating agent is included as a lubricating component, the amount of such coating agent is preferably 2.0% by mass or more, 2.5% by mass or more, or 3.0% by mass or more, relative to the total amount of the second agent, and also preferably 20% by mass or less, 15% by mass or less, or 10% by mass or less, from the viewpoint of protective performance of the coating.

[0052] When the above-mentioned water-soluble polymer is included as a lubricating component, the amount of such water-soluble polymer can be 0.05% by mass or more, 0.10% by mass or more, or 0.20% by mass or more, relative to the total amount of the second agent, from the viewpoint of protective performance of the film, etc., or it can be 5.0% by mass or less, 4.0% by mass or less, 3.0% by mass or less, 2.0% by mass or less, or 1.0% by mass or less.

[0053] <Dosage form of the second drug> There are no particular restrictions on the dosage form of the second agent in this disclosure. For example, the dosage forms may include a single-phase system composed of an oil phase, a two-phase system composed of an oil-in-water emulsion composition or a water-in-oil emulsion composition, or a non-emulsified two-phase system. Here, a single-phase system composed of an oil phase is typically in an anhydrous form. In this disclosure, "anhydrous" means not only that the composition does not contain water, but also that the water content is low, i.e., 10% by mass or less, 5% by mass or less, 2% by mass or less, 1% by mass or less, or 0.1% by mass or less. Furthermore, a non-emulsified two-phase system may include a water-in-oil composition in which water droplets are forcibly dispersed in an oil-containing dispersion medium by shaking a liquid that has been separated into water and oil, or an oil-in-water composition in which oil droplets are forcibly dispersed in a water-containing dispersion medium.

[0054] Each of these dosage forms can be prepared as appropriate by conventional methods using known materials such as oil, emulsifier, and water.

[0055] (Oil content) Examples of oils include liquid oils and fats, solid oils and fats, waxes, hydrocarbon oils, silicone oils, and polar oils. These oils can be used individually or in combination of two or more types.

[0056] For example, as the silicone oil, chain-like silicones such as dimethylpolysiloxane (dimethicone), methylphenylpolysiloxane, and methylhydrogenpolysiloxane; and cyclic silicones such as octamethylcyclotetrasiloxane, decamethylcyclopentasiloxane, and dodecamethylcyclohexasiloxane can be used. Alternatively, as the silicone oil, a first unsaturated organopolysiloxane and a first hydride-functionalized polysiloxane, which may be used in the first agent described later, may be used. The unsaturated organopolysiloxane and hydride-functionalized polysiloxane in the second agent may be referred to as a second unsaturated organopolysiloxane and a second hydride-functionalized polysiloxane in order to distinguish them from the first unsaturated organopolysiloxane and the first hydride-functionalized polysiloxane in the first agent.

[0057] There are no particular restrictions on the amount of oil used; for example, it can be adjusted as appropriate depending on the type of formulation used.

[0058] (emulsifier) As emulsifiers, for example, anionic, cationic, amphoteric, or nonionic emulsifiers can be used. Emulsifiers can be used alone or in combination of two or more. Here, the term emulsifier in this disclosure refers to an agent having emulsifying function (surfactant activity), and can also include agents generally referred to as surfactants. If a water-soluble polymer emulsifier is included as a lubricating component, other emulsifiers do not need to be used, or they may be used in combination with other emulsifiers.

[0059] Specifically, examples of emulsifiers include at least one selected from the group consisting of hydrocarbon surfactants, silicone surfactants, and amphiphilic powders.

[0060] Examples of hydrocarbon surfactants include polyoxyethylene alkyl ethers, polyoxyethylene steryl ethers, polyoxyethylene fatty acid esters, polyoxyethylene polyhydric alcohol fatty acid esters, polyoxyethylene hydrogenated castor oil, polyoxyethylene sorbitan fatty acid esters, glycol fatty acid esters, glycerin fatty acid esters, sorbitan fatty acid esters, sucrose fatty acid esters, and polyglycerin fatty acid esters.

[0061] Examples of silicone-based surfactants include polyether-modified silicones and alkyl-comodified polyether-modified silicones.

[0062] There are no particular restrictions on the amount of emulsifier to be added. For example, from the viewpoint of emulsification stability, the amount can be 0.01% by mass or more, 0.05% by mass or more, 0.1% by mass or more, or 0.2% by mass or more, relative to the total amount of the second component. There are no particular restrictions on the upper limit of the amount of emulsifier to be added. For example, it can be 5% by mass or less, 4% by mass or less, 3% by mass or less, 2% by mass or less, or 1% by mass or less.

[0063] (water) The water that can be used in the second agent of this disclosure is not particularly limited, but for example, water used in cosmetics or quasi-drugs can be used. For example, deionized water, distilled water, ultrapure water, and tap water can be used.

[0064] There are no particular restrictions on the amount of water used; for example, it can be adjusted as appropriate depending on the type of formulation used.

[0065] 《Topical body correction film-forming agent》 The second agent of the present disclosure described above can be suitably used as the second agent in a coating-type body corrective film-forming agent comprising the first agent and the second agent. Such a forming agent can form a body corrective film by, for example, applying the first agent to the body surface to form a first agent layer, and then applying the second agent to the first agent layer to crosslink the first agent layer.

[0066] In some embodiments, the coating performance of the coating-type body corrective film-forming agent can be evaluated by viscosity using a Type B viscometer (Shibaura Systems Co., Ltd., Bismetron). The viscosity of the first and second components of the coating-type body corrective film-forming agent of this disclosure immediately after preparation, measured under conditions of 25°C and 60 revolutions / min (rotor No. 3 or No. 4), is, for example, 100 mPa·s or more, 500 mPa·s or more, 1,000 mPa·s or more, 2,000 mPa·s or more, 5,000 mPa·s or more, 7,500 mPa·s or more, 10,000 mPa·s or more, or 15,000 mPa·s or more. It can be set to 1,000,000 mPa·s or less, 750,000 mPa·s or less, 500,000 mPa·s or less, 250,000 mPa·s or less, 200,000 mPa·s or less, 175,000 mPa·s or less, 150,000 mPa·s or less, 125,000 mPa·s or less, 100,000 mPa·s or less, or 80,000 mPa·s or less. In particular, from the viewpoint of smooth application performance and suppression of dripping from the skin, the first and second components of the application-type body corrective film-forming agent preferably have a viscosity of 20,000 mPa·s or less, 15,000 mPa·s or less, or 10,000 mPa·s or less immediately after preparation, and preferably have a viscosity of 3,000 mPa·s or more, 5,000 mPa·s or more, or 7,000 mPa·s or more.

[0067] In some embodiments, the viscosity of the first and second components of the coating-type body corrective film-forming agent of this disclosure, measured at 25°C and 60 revolutions / minute (rotor No. 3), after two weeks is preferably 50,000 mPa·s or less, 30,000 mPa·s or less, or 15,000 mPa·s or less, and preferably 5,000 mPa·s or more, 7,000 mPa·s or more, or 10,000 mPa·s or more, from the viewpoint of smooth application performance and suppression of dripping from the skin.

[0068] In some embodiments, the coating performance of a body correction film can be evaluated, for example, by whether or not the body correction film tears when peeled from the skin. For example, if the tearing of the applied body correction film is 15% or less, 10% or less, or 5% or less of the total, the coating performance can be said to be excellent. There is no particular limit on the lower limit of tearing, but it can be, for example, 0% or more or greater than 0%. In addition, the coating performance can also be evaluated by tensile strength, elongation at break, etc., as described later.

[0069] <First Agent> The first agent constituting the coating-type body corrective film-forming agent of this disclosure comprises at least one selected from the group consisting of a first unsaturated organopolysiloxane and a first hydride-functionalized polysiloxane. However, if the first agent comprises only the first unsaturated organopolysiloxane from the first unsaturated organopolysiloxane and the first hydride-functionalized polysiloxane, the second agent described above comprises the second hydride-functionalized polysiloxane described later. Furthermore, if the first agent comprises only the first hydride-functionalized polysiloxane from the first unsaturated organopolysiloxane and the first hydride-functionalized polysiloxane, the second agent comprises the second unsaturated organopolysiloxane.

[0070] The first agent may be, for example, a single-phase system composed of an oil phase in an anhydrous form, a two-phase system composed of an oil-in-water emulsion composition or a water-in-oil emulsion composition, or a non-emulsified oil-in-water or water-in-oil two-phase system. In particular, from the viewpoint of long-term storage, drying properties after application of the first agent to the body surface, and crosslinking properties, it is advantageous for the first agent to be a single-phase system composed of an oil phase in an anhydrous form.

[0071] Each of these dosage forms can be prepared as appropriate by conventional methods using known materials such as oils, emulsifiers, and water as described above.

[0072] Since the first agent is applied to the body surface by application, it is preferable that it has a glass transition temperature below body temperature from the viewpoint of application performance. For example, the glass transition temperature can be 37°C or lower, 25°C or lower, 10°C or lower, or 0°C or lower. There are no particular restrictions on the lower limit of the glass transition temperature, but for example, it can be -30°C or higher, -20°C or higher, or -10°C or higher. Here, "glass transition temperature" refers to the temperature at which the transition from a solid state to a liquid state occurs, and can be measured, for example, using a differential scanning calorimeter (DSC) in accordance with ASTM D3418-03.

[0073] (First unsaturated organopolysiloxane) The first unsaturated organopolysiloxane is not particularly limited, and examples include one or more organopolysiloxanes having at least two carbon-carbon double bonds or at least one carbon-carbon triple bond in the molecule. Preferably, such unsaturated organopolysiloxanes include one or more organopolysiloxanes having, on average, at least two alkenyl functional groups and a viscosity of 10,000 to 2,000,000 cst at 25°C. Hereinafter, "carbon-carbon double bond" and "carbon-carbon triple bond" may be simply referred to as "double bond" and "triple bond." The first unsaturated organopolysiloxane can be used alone or in combination of two or more.

[0074] Such organopolysiloxanes may contain double or triple bonds in the terminal units of the polymer, in the non-terminal monomer units of the polymer, or in a combination thereof, with the presence of double or triple bonds in the non-terminal monomer units of the polymer being particularly preferred.

[0075] In one embodiment, the double bond-containing monomer units in the organopolysiloxane may be separated on average by 40 monomer units or more, 200 monomer units or more, 400 monomer units or more, 1,000 monomer units or more, or 2,000 monomer units or more.

[0076] In one embodiment, the amount of double-bond or triple-bond-containing monomer units in the organopolysiloxane having a double-bond or triple-bond can be, for example, 0.01% by mass or more, or 0.03% by mass or more, and 2% by mass or less, or 0.6% by mass or less.

[0077] In some embodiments, the vinyl equivalent of an organopolysiloxane having double or triple bonds can be, for example, 0.005 or more or 0.01 or more per kilogram, and 0.5 or less or 0.25 or less. The approximate molar amount of double or triple bonds in the organopolysiloxane can be calculated based on the average molecular weight of the organopolysiloxane. Herein, the average molecular weight or molecular mass of each component disclosed herein is generally provided by the supplier of each component and can be expressed in units of Daltons (Da) or equivalent g / mol.

[0078] In one embodiment, the first unsaturated organopolysiloxane can have a viscosity of 10,000 to 2,000,000 cst at 25°C. The lower limit of such viscosity is preferably 20,000 cst or more, 40,000 cst or more, 60,000 cst or more, 80,000 cst or more, or 100,000 cst or more, and more preferably 125,000 cst or more or 150,000 cst or more. The upper limit of viscosity is preferably 1,000,000 cst or less, 500,000 cst or less, 450,000 cst or less, 400,000 cst or less, 350,000 cst or less, 300,000 cst or less, or 250,000 cst or less, more preferably 200,000 cst or less or 180,000 cst or less, and even more preferably 165,000 cst or less.

[0079] In one embodiment, the first unsaturated organopolysiloxane can have an average molecular weight of 60,000 Da to 500,000 Da. The lower limit of such average molecular weight is preferably 72,000 Da or more, 84,000 Da or more, 96,000 Da or more, or 100,000 Da or more, and more preferably 140,000 Da or more, or 150,000 Da or more. The upper limit of the average molecular weight is preferably 200,000 Da or less, 190,000 Da or less, 180,000 Da or less, or 170,000 Da or less, more preferably 160,000 Da or less, and even more preferably 155,000 Da or less.

[0080] As the first unsaturated organopolysiloxane, for example, at least one unsaturated organopolysiloxane selected from the group consisting of organopolysiloxanes having vinyl groups, vinyl-terminated organopolysiloxanes, and organopolysiloxanes having vinyl-terminated branched chains can be used.

[0081] Specifically, examples include vinyl-terminated polydimethylsiloxane, vinyl-terminated diphenylsiloxane-dimethylsiloxane copolymer, vinyl-terminated polyphenylmethylsiloxane, vinylphenylmethyl-terminated vinylphenylsiloxane-phenylmethylsiloxane copolymer, vinyl-terminated trifluoropropylmethylsiloxane-dimethylsiloxane copolymer, vinyl-terminated diethylsiloxane-dimethylsiloxane copolymer, vinyl-methylsiloxane-dimethylsiloxane copolymer, trimethylsiloxy-terminated vinylmethylsiloxane-dimethylsiloxane copolymer, silanol-terminated vinylmethylsiloxane-dimethylsiloxane copolymer, vinyl methylsiloxane homopolymer, vinyl T-structure polymer, vinyl Q-structure polymer, monovinyl-terminated polydimethylsiloxane, vinyl methylsiloxane terpolymer, and vinyl methoxysilane homopolymer. The first unsaturated organopolysiloxane can be used alone or in combination of two or more. Among these, vinyl-terminated polydimethylsiloxane is preferred, and vinyl dimethicone (divinyldimethicone) is more preferred. In this disclosure, "terminated" refers to either a single-terminated or double-terminated material. When distinguishing between these, for example, "vinyl single-terminated" and "vinyl double-terminated" can be used.

[0082] The amount of the first unsaturated organopolysiloxane in the first agent can be adjusted as appropriate according to the required film performance, etc., and there are no particular restrictions. For example, the amount of the first unsaturated organopolysiloxane can be 5% by mass or more, 10% by mass or more, 20% by mass or more, 30% by mass or more, 35% by mass or more, or 40% by mass or more relative to the entire first agent, and can be 90% by mass or less, 80% by mass or less, 70% by mass or less, 60% by mass or less, 50% by mass or less, or 45% by mass or less.

[0083] (First hydride-functionalized polysiloxane) There is no particular limitation on the first hydride-functionalized polysiloxane. For example, the compound of the following formula 1 can be cited. The first hydride-functionalized polysiloxane can be used alone or in combination of two or more kinds: [Chemical formula]

[0084] In formula 1, R 1b , R 2b , R 3b , R 4b , R 5b , R 6b , R 7b , R 8b , R 9b and R 10b are each independently selected from hydrogen, C 1-20 alkyl, C 2-20 alkenyl, C 5-10 aryl, hydroxyl, or C 1-20 alkoxy, and m and n are each independently an integer of 10 to 6,000. However, at least one of R 1b , R 2b , R 3b , R 4b , R 5b , R 6b , R 7b , R 8b , R 9b and R 10b is hydrogen.

[0085] In some embodiments, at least one of R 1b , R 2b , R 3b , R 4b , R 5b , R 6b , R 7b , R 8b , R 9b and R 10b is hydrogen, and the rest are C 1-20 alkyl.

[0086] In some embodiments, R 1b , R 2b , R 3b, R 4b , R 5b , R 6b , R 7b , R 8b , R 9b and R 10b At least two of them are hydrogen atoms (for example, two Si-H units per functionalized hydride polysiloxane molecule).

[0087] In other embodiments, R 1b , R 2b , R 3b , R 4b , R 5b , R 6b , R 7b , R 8b , R 9b and R 10b At least three of them are hydrogen atoms (for example, three Si-H units per functionalized hydride polysiloxane molecule).

[0088] In some embodiments, R 1b , R 2b , R 3b , R 4b , R 5b , R 6b , R 7b , R 8b , R 9b and R 10b At least two of them are hydrogen atoms (e.g., two Si-H units per functionalized hydride polysiloxane molecule), and the rest are C 1-20 It is alkyl.

[0089] In other embodiments, R 1b , R 2b , R 3b , R 4b , R 5b , R 6b , R 7b , R 8b , R 9b and R 10b At least three of them are hydrogen (e.g., three Si-H units per functionalized hydride polysiloxane molecule), and the rest are C 1-20 It is alkyl.

[0090] In some embodiments, R 4b , R 5b , R 9b and R 10b at least two of are hydrogen (e.g., two Si-H units per functionalized hydridopolysiloxane molecule), and the remainder are C 1-20 alkyl.

[0091] In other embodiments, R 4b , R 5b , R 9b and R 10b at least three of are hydrogen (e.g., three Si-H units per functionalized hydridopolysiloxane molecule), and the remainder are C 1-20 alkyl.

[0092] In some embodiments, the sum of m and n is an integer from 10 to 1,300, 10 to 1,100, 10 to 600, 15 to 500, 15 to 400, 20 to 300, 20 to 200, 25 to 100, 25 to 75, 30 to 50, or 40 to 45.

[0093] In some embodiments, examples of the first hydridofunctionalized polysiloxane include organopolysiloxanes hydrogenated at non-terminal and / or terminal positions, and are composed of one or more organopolysiloxanes having at least two Si-H units in the molecule. Preferably, examples include one or more organopolysiloxanes having an average of at least two Si-H units and a viscosity of 2 to 100,000 cst at 25°C.

[0094] In one embodiment, the organopolysiloxane having Si-H units may contain such Si-H units in the terminal units of the polymer, in the non-terminal monomer units of the polymer, or in a combination thereof. Among them, it is preferable that the Si-H units are contained in the non-terminal monomer units of the polymer. In this case, the first hydridofunctionalized polysiloxane may be alkyl-terminated. For example, in Formula 1, one or both of R 2b and R 7b may be C 1-20 alkyl.

[0095] In one embodiment, in Formula 1, R 1b , R 2b , R 3b , R 6b , R 7b and R 8b one, two, three, four, five, or six of may be C 1-20 alkyl.

[0096] In one embodiment, R 1b , R 2b , R 3b , R 4b , R 5b , R 6b , R 7b , R 8b and R 10b are each C 1-20 alkyl, for example, C1 alkyl (e.g., methyl), and R 9b may be hydrogen.

[0097] In one embodiment, R 1b , R 2b , R 3b , R 4b , R 5b , R 6b , R 7b , R 8b and R 9b are each C 1-20 alkyl, for example, C1 alkyl (e.g., methyl), and R 10b may be hydrogen.

[0098] In certain embodiments, the Si-H containing monomer units in the organopolysiloxane may be, on average, separated by one monomer unit or more, two monomer units or more, five monomer units or more, ten monomer units or more, twenty monomer units or more, forty monomer units or more, two hundred monomer units or more, four hundred monomer units or more, one thousand monomer units or more, or two thousand monomer units or more.

[0099] In one embodiment, the amount of Si-H-containing monomer units in the organopolysiloxane having Si-H units can be 0.003% by mass or more, 0.01% by mass or more, 0.1% by mass or more, 1% by mass or more, 3% by mass or more, 5% by mass or more, 10% by mass or more, 20% by mass or more, or 26% by mass or more, and can also be 50% by mass or less, 45% by mass or less, 40% by mass or less, 35% by mass or less, 30% by mass or less, or 27% by mass or less.

[0100] In one embodiment, the Si-H content of the organopolysiloxane having Si-H units can be 0.1 mmol / g or more, 0.5 mmol / g or more, 1 mmol / g or more, 2 mmol / g or more, 3 mmol / g or more, or 4 mmol / g or more, and can be 20 mmol / g or less, 10 mmol / g or less, 9 mmol / g or less, 8 mmol / g or less, 7 mmol / g or less, 6 mmol / g or less, or 5 mmol / g or less. The approximate molar amount of Si-H units in the organopolysiloxane can be calculated based on the average molecular weight of the organopolysiloxane.

[0101] In one embodiment, the first hydride-functionalized polysiloxane can have a viscosity of 2 to 500,000 cst at 25°C. The lower limit of such viscosity is preferably 3 cst or more, 4 cst or more, 5 cst or more, 10 cst or more, 12 cst or more, 15 cst or more, 20 cst or more, 25 cst or more, or 30 cst or more, and more preferably 40 cst or more. The upper limit of viscosity is preferably 200,000 cst or less, 100,000 cst or less, 50,000 cst or less, 20,000 cst or less, 10,000 cst or less, 5,000 cst or less, 2,000 cst or less, or 1,000 cst or less, and more preferably 500 cst or less. The viscosity of the hydride-functionalized polysiloxane is preferably in the range of 45 to 100 cst, or 45 to 50 cst, at 25°C.

[0102] In one embodiment, the hydride-functionalized polysiloxane can have an average molecular weight of 400 to 500,000 Da. The lower limit of such average molecular weight is preferably 500 Da or more, 800 Da or more, 900 Da or more, 1,000 Da or more, 1,200 Da or more, 1,400 Da or more, 1,600 Da or more, 1,800 Da or more, 2,000 Da or more, or 2,200 Da or more, and more preferably 2,300 Da or more. The upper limit of the average molecular weight is preferably 250,000 Da or less, 140,000 Da or less, 100,000 Da or less, 72,000 Da or less, 62,700 Da or less, 60,000 Da or less, 50,000 Da or less, 49,500 Da or less, 36,000 Da or less, 28,000 Da or less, 25,000 Da or less, 20,000 Da or less, 15,000 Da or less, 10,000 Da or less, 5,000 Da or less, or 4,000 Da or less, and more preferably 2,500 Da or less.

[0103] The first hydride-functionalized polysiloxane is not limited to the following, but can be at least one selected from the group consisting of hydride-terminated polydimethylsiloxane, hydride-terminated polyphenyl-(dimethylhydrosiloxy)siloxane, hydride-terminated methylhydrosiloxane-phenylmethylsiloxane copolymer, trimethylsiloxy-terminated methylhydrosiloxane-dimethylsiloxane copolymer, polymethylhydrosiloxane, trimethylsiloxy-terminated polyethylhydrosiloxane, triethylsiloxane, methylhydrosiloxane-phenyloctylmethylsiloxane copolymer, and methylhydrosiloxane-phenyloctylmethylsiloxane terpolymer. Among these, hydride-terminated polydimethylsiloxane is preferred, and hydrogen dimethicone is more preferred.

[0104] The amount of the first hydride-functionalized polysiloxane in the first agent can be adjusted as appropriate according to the required film performance, etc., and there are no particular restrictions. For example, the amount of the first hydride-functionalized polysiloxane can be 1% by mass or more, 3% by mass or more, or 5% by mass or more relative to the entire first agent, and can be 75% by mass or less, 60% by mass or less, 50% by mass or less, 40% by mass or less, 30% by mass or less, 20% by mass or less, or 10% by mass or less.

[0105] (Other polymers) The first agent may optionally contain other polymers other than the first unsaturated organopolysiloxane and the first hydride-functionalized polysiloxane. The other polymers may be used alone or in combination of two or more.

[0106] In one embodiment, the other polymer can have a viscosity of 0.7 cst to 50,000 cst at 25°C. The lower limit of such viscosity can be 1 cst or more, 6 cst or more, 10 cst or more, 20 cst or more, 50 cst or more, 100 cst or more, 200 cst or more, 300 cst or more, 400 cst or more, 750 cst or more, 1,000 cst or more, 1,500 cst or more, 2,000 cst or more, 2,500 cst or more, 3,000 cst or more, 3,500 cst or more, or 4,000 cst or more. The upper limit of viscosity can be 45,000 cst or less, 40,000 cst or less, 35,000 cst or less, 30,000 cst or less, 25,000 cst or less, 20,000 cst or less, 15,000 cst or less, 12,000 cst or less, 10,000 cst or less, 5,000 cst or less, 4,000 cst or less, 2,000 cst or less, 1,500 cst or less, or 1,000 cst or less.

[0107] In one embodiment, the other polymer may have an average molecular weight of 180 Da to 80,000 Da. The lower limit of such average molecular weight can be 500 Da or more, 800 Da or more, 1,500 Da or more, 3,000 Da or more, 6,000 Da or more, 9,400 Da or more, 10,000 Da or more, 15,000 Da or more, 20,000 Da or more, 30,000 Da or more, 40,000 Da or more, 50,000 Da or more, 55,000 Da or more, 60,000 Da or more, or 62,000 Da or more. The upper limit of the average molecular weight can be 75,000 Da or less, 70,000 Da or less, 65,000 Da or less, or 63,000 Da or less.

[0108] Other polymers that are preferable include one or more organopolysiloxanes having, on average, at least one alkenyl functional group and a viscosity of 0.7 to 50,000 cst at 25°C.

[0109] Specifically, other polymers include, for example, vinyl-terminated polydimethylsiloxane, vinyl-terminated diphenylsiloxane-dimethylsiloxane copolymer, vinyl-terminated polyphenylmethylsiloxane, vinylphenylmethyl-terminated vinylphenylsiloxane-phenylmethylsiloxane copolymer, vinyl-terminated trifluoropropylmethylsiloxane-dimethylsiloxane copolymer, vinyl-terminated diethylsiloxane-dimethylsiloxane copolymer, vinylmethylsiloxane-dimethylsiloxane copolymer, trimethylsiloxy-terminated vinylmethylsiloxane-dimethylsiloxane copolymer, and silanol-terminated vinylmethylsiloxane-dimethylsiloxane copolymer. At least one selected from xan copolymers, vinyl-terminated vinyl rubber, vinyl methylsiloxane homopolymers, vinyl T-structure polymers, vinyl Q-structure polymers, unsaturated organic polymers (e.g., unsaturated fatty alcohols, unsaturated fatty acids, unsaturated fatty esters, unsaturated fatty amides, unsaturated fatty urethanes, unsaturated fatty ureas, ceramides, crocetin, lecithin, and sphingosine), monovinyl-terminated polydimethylsiloxanes, vinyl methylsiloxane terpolymers, vinyl methoxysilane homopolymers, vinyl-terminated polyalkylsiloxane polymers, and vinyl-terminated polyalkoxysiloxane polymers can be used. Among these, vinyl-terminated polydimethylsiloxanes are preferred, and divinyldimethicone and 1,3-divinyltetramethyldisiloxane are more preferred.

[0110] The amount of other polymers in the first agent can be adjusted as appropriate according to the required film performance, etc., and there are no particular restrictions. For example, the amount of other polymers can be 0.01% by mass or more, 0.1% by mass or more, 0.3% by mass or more, or 0.5% by mass or more relative to the entire first agent, and can be 20% by mass or less, 15% by mass or less, or 10% by mass or less.

[0111] <Ratio of functional groups in the first unsaturated organopolysiloxane, the first hydride-functionalized polysiloxane, and other polymers> In one embodiment, the molar ratio of the Si-H functional group derived from the first hydride-functionalized polysiloxane to the alkenyl functional group derived from the first unsaturated organopolysiloxane is preferably 60:1 to 1:5, and more preferably 45:1 to 15:1.

[0112] In one embodiment, the molar ratio of Si-H functional groups derived from the first hydride-functionalized polysiloxane to alkenyl functional groups derived from the other polymer is preferably 60:1 to 1:5, and more preferably 45:1 to 15:1.

[0113] In one embodiment, the molar ratio of alkenyl functional groups derived from the first unsaturated organopolysiloxane to alkenyl functional groups derived from the other polymer is preferably 100:1 to 1:100, and more preferably 10:1 to 1:10.

[0114] <Second drug> The coating-type body correction film-forming agent of this disclosure can use the second agent described above.

[0115] Furthermore, the second agent can similarly incorporate other polymers mentioned above that can be incorporated into the first agent.

[0116] In the second agent, when a second unsaturated organopolysiloxane and other polymers are used, the ratio of their functional groups can be the same as the ratio of functional groups in the first unsaturated organopolysiloxane and other polymers described above.

[0117] <Optional ingredients> The coating-type body corrective film-forming agent of this disclosure may contain various components as appropriate, provided that they do not affect the effects of this disclosure.

[0118] There are no particular restrictions on optional components, but examples include texture modifiers, tack modifiers, spreadability enhancers, diluents, adhesion modifiers, emulsifiers (surfactants), solvents, humectants, preservatives, fibers, pigments, dyes, components that thicken the aqueous or oil phase (thickeners), protective colloids, fillers, skin permeability enhancers, optical modifiers, scattering agents, adsorbents, magnetic materials, gas transport modifiers, liquid transport modifiers, pH modifiers, sensitizers, and aesthetic modifiers. Optional components can be used individually or in combination of two or more.

[0119] Examples of fillers include at least one selected from carbon, silver, mica, zinc sulfide, zinc oxide, titanium dioxide, aluminum oxide, clay, chalk, talc, calcite (e.g., CaCO3), barium sulfate, zirconium dioxide, polymer beads, silica (e.g., fumed silica, silicic acid, or anhydrous silica), silica aluminate, and calcium silicate, which may be surface-treated. Such fillers can improve the physical properties (e.g., strength) of the body correction film and can also act as viscosity modifiers. Among these, surface-treated silica, such as silica treated with a surface treatment agent such as hexamethyldisilazane, polydimethylsiloxane, hexadecylsilane, or methacrylatesilane, is preferred as a filler. Fumed silica is also preferred, and fumed silica surface-treated with hexamethyldisilazane, for example, can be suitably used.

[0120] In one embodiment, the filler is 50-500m 2 It can have a specific surface area of ​​1 / g. The specific surface area of ​​the filler is 100 to 350 m². 2 It is preferable that the value be / g, and 135-250m 2 It is more preferable that the concentration is / g. Here, the specific surface area of ​​the filler can be calculated using the BET method.

[0121] In one embodiment, the filler may have an area-circular particle diameter of 1 nm to 20 μm. Preferably, the area-circular particle diameter of the filler is 2 nm to 1 μm, and more preferably 5 nm to 50 nm. Here, the area-circular particle diameter of the filler can refer to the particle diameter when converted to a circular particle having the same area as the projected area of ​​the filler particles observed with a transmission electron microscope, for example. Such an area-circular particle diameter can be defined as the average value of 10 or more particles.

[0122] The amount of filler added can be, for example, 1% by mass or more, 3% by mass or more, or 5% by mass or more, relative to the total amount of the first or second component, and can be 25% by mass or less, 15% by mass or less, or 10% by mass or less.

[0123] From the viewpoint of reinforcing properties of the body correction film, the mass ratio of the total amount of the first and second unsaturated organopolysiloxanes, the first and second hydride-functionalized polysiloxanes, and other polymers to the filler can be 100:1 to 1:1, preferably 50:1 to 2:1, more preferably 15:1 to 3:1, even more preferably 10:1 to 4:1, and particularly preferably 5:1 to 9:1.

[0124] It is preferable that at least one of the optional components, selected from pigments, dyes, and fillers, be incorporated into the first agent. In particular, with regard to pigments and dyes, if they are incorporated into the second agent, when the second agent is applied to the surface to which the first agent is applied, it may harden midway through the process, causing the pigment or dye to localize and potentially resulting in uneven coloring. From the viewpoint of suppressing uneven coloring, it is advantageous to incorporate pigments and dyes into the first agent. Furthermore, pigments, dyes, and fillers may be incorporated into the second agent to the extent that they do not cause uneven coloring, but it is advantageous that they are not included in the second agent.

[0125] In some embodiments, the forming agent of the present disclosure may further incorporate one or more agents with respect to the first and / or second agent. Examples of such agents include cosmetics, therapeutic agents, irritant responsive agents, and drug delivery agents.

[0126] Suitable cosmetic agents include, for example, moisturizers other than those having a sugar skeleton as described above, UV absorbers, skin protectants, skin soothing agents, skin whitening agents, skin glossing agents, skin emollients, skin smoothing agents, skin bleaching agents, skin exfoliating agents, skin tightening agents, cosmetic agents, vitamins, antioxidants, cell signaling agents, cell regulators, cell interaction agents, skin sunscreens, anti-aging agents, wrinkle inhibitors, spot reducers, α-hydroxy acids, β-hydroxy acids, and ceramides.

[0127] Suitable therapeutic agents include, for example, pain relievers, analgesics, antipruritic agents, antiacids (e.g., β-hydroxy acids, salicylic acid, benzoyl peroxide), anti-inflammatory agents, antihistamines, corticosteroids, NSAIDs (non-steroidal anti-inflammatory drugs), antiseptics, antibiotics, antibacterial agents, antifungal agents, antiviral agents, antiallergic agents, anti-irritants, insect repellents, phototherapy agents, blood coagulants, antineoplastic agents, immune system enhancers, immune system suppressants, coal tar, anthraline, fluocinonide, methotrexate, cyclosporine, pimecrolimus, tacrolimus, azathioprine, fluorouracil, ceramides, counter-irritants, and skin cooling compounds.

[0128] Suitable agents include, for example, antioxidants, vitamins, vitamin D3 analogs, retinoids, minerals, mineral oils, petrolatum, fatty acids, plant extracts, polypeptides, antibodies, proteins, sugars, humectants, and emollients other than the emollient oils mentioned above.

[0129] Lubricating layer forming agent The lubricating layer-forming agent of this disclosure contains a lubricating component and is applied to the formed body correction film. The lubricating component and its amount can be the same as those of the second agent described above. The upper limit of the amount of the lubricating component can be 100% by mass or less, less than 100% by mass, 90% by mass or less, 80% by mass or less, 70% by mass or less, or 60% by mass or less, relative to the total amount of the lubricating layer-forming agent.

[0130] <Formulation of lubricating layer-forming agent> There are no particular limitations on the dosage form of the lubricating layer-forming agent of this disclosure. Examples include a single-phase system composed of an oil phase or an aqueous phase, a two-phase system composed of an oil-in-water emulsion composition or a water-in-oil emulsion composition, or a non-emulsified oil-in-water or water-in-oil two-phase dosage form.

[0131] Each of these dosage forms can be prepared as appropriate by conventional methods using known materials such as oil, emulsifier, and water. The oil, emulsifier, and water, and their proportions, can be similarly adopted to those of the second agent described above. Furthermore, the lubricating layer-forming agent can be similarly formulated with any optional components that can be incorporated into the first and second agents described above.

[0132] If the coating-type body corrective film-forming agent is a two-component formula containing a first agent and a second agent, as described above, the lubricating layer-forming agent can be used as a third agent. If the coating-type body corrective film-forming agent is a single-component formula, the lubricating layer-forming agent can be used as a second agent.

[0133] Instructions for using topical body correction film-forming agents The topical body corrective film-forming agents of this disclosure can be used, for example, for cosmetic or medical purposes. However, the methods of use of the topical body corrective film-forming agents of this disclosure do not include methods of surgery, treatment, or diagnosis of human beings.

[0134] There are no particular limitations on the method of using the coating-type body corrective film-forming agent of this disclosure. For example, a method in which the first agent is applied to the body surface to form a first agent layer, and then the second agent is applied on the first agent layer and crosslinked to form a body corrective film; a method in which the second agent is applied to the body surface to form a second agent layer, and then the first agent is applied on the second agent layer and crosslinked to form a body corrective film; or a method in which the first agent and the second agent are mixed to prepare a mixture, and then the mixture is applied to the body surface and crosslinked to form a body corrective film. From the viewpoint of obtaining a uniform body corrective film with little unevenness, the method of applying the first agent to the body surface to form a first agent layer, and then the second agent is applied on this first agent layer and crosslinked to form a body corrective film is preferred. Here, the materials described above can be used in the same way for the first agent and the second agent.

[0135] This method may be performed in a single step, or it may be repeated multiple times on the formed body correction film.

[0136] In some embodiments, the cosmetic may be applied to the body surface before applying the first agent, the second agent, or a mixture comprising the first and second agents to the body surface; the first agent may be applied to the body surface to form a first agent layer, the cosmetic may be applied on the first agent layer, and then the second agent may be applied to cover the cosmetic; the second agent may be applied to the body surface to form a second agent layer, the cosmetic may be applied on the second agent layer, and then the first agent may be applied to cover the cosmetic; or, a body corrective film may be formed, and then the cosmetic may be applied to the film.

[0137] There are no particular restrictions on what can be used as a cosmetic product. For example, skincare cosmetics such as serums, lotions, and emulsions, sunscreen cosmetics, makeup bases, or makeup cosmetics such as foundations, lip glosses, lipsticks, eyeshadows, and nail polishes, or cosmetics that combine two or more of these functions, can be used.

[0138] Furthermore, in some embodiments, the method of using the topical body corrective film-forming agent of this disclosure can also be used as a cosmetic method. Note that "cosmetic method" means applying the topical body corrective film-forming agent of this disclosure to the body surface to form a body corrective film, thereby beautifying or improving the condition of the body surface, and is distinct from methods of surgery, treatment, or diagnosis of a human being.

[0139] There are no particular restrictions on the method of applying the first or second agent to the body surface, the cosmetic application layer, or the first or second agent layer. For example, methods such as spreading with fingers, spray application, or transfer can be employed.

[0140] Furthermore, when the first and second agents are separated into water and oil, it is preferable to shake them to forcibly create a two-phase system (oil-in-water or water-in-oil) from the viewpoint of protecting the body's protective coating from external stimuli.

[0141] <Application area> The topical body corrective film-forming agent disclosed herein can be applied to any part of the body, i.e., any part on the body surface. For example, it can be applied as appropriate to the skin surface of the face (lips, eyes, nose, cheeks, forehead, etc.), neck, ears, hands, arms, legs, feet, chest, abdomen, back, etc. Here, skin includes nails, which are formed by the hardening of the keratinized layer of the epidermis.

[0142] Instructions for using lubricating layer-forming agents There are no particular restrictions on the method of using the lubricating layer-forming agent of this disclosure. For example, a crosslinking reactive component constituting a body corrective coating and a crosslinking component that crosslinks the crosslinking reactive component may be applied to the body surface to form a body corrective coating, and then the lubricating layer-forming agent may be applied to the coating; or, after forming a body corrective coating, a cosmetic may be applied to the coating, and then the lubricating layer-forming agent may be applied to cover the cosmetic. The application sites for the body corrective coating can be similar to those mentioned above.

[0143] Cosmetics that can be applied to the film can be the same as those described above. Alternatively, the lubricating layer-forming agent itself may function as a cosmetic.

[0144] There are no particular restrictions on the method of applying a lubricating layer-forming agent to a body correction film or a cosmetic application layer. For example, methods such as spreading it with a finger, spray application, or transfer can be employed.

[0145] Furthermore, when the lubricating layer-forming agent is separated into water and oil, it is preferable to shake the lubricating layer-forming agent to forcibly convert it into a two-phase system (oil-in-water or water-in-oil) from the viewpoint of forming a uniform lubricating layer.

[0146] Kit equipped with a topical body correction film-forming agent. The coating-type body corrective film-forming agent of this disclosure can be provided as a kit having the above-described first agent and second agent constituting such a forming agent. In addition to the first agent and second agent, the kit may have any other components, such as a component for facilitating the application of the first agent etc. to the body surface, and the above-described various cosmetics. Alternatively, the kit may have the above-described lubricating layer-forming agent.

[0147] Optional components include, for example, an instruction manual, a brush, cotton swabs, a cutter, scissors, the various cosmetics mentioned above, a cleanser for removing the body correction film from the body surface, a mirror, etc. Here, "instruction manual" can include not only the general instruction manual attached to the kit in document form, but also, for example, instructions printed on the packaging container that houses the kit, or on the packaging container of the tube into which the first agent is injected, etc.

[0148] In one embodiment, to prevent contact between the first and second agents, the kit may contain the agents in separate containers, or in separate containers within each of two or more compartments. Furthermore, these contained agents may be configured to be applied one at a time, or to be mixed together before or during use.

[0149] In one embodiment, a one-component coating-type body correcting film-forming agent can be provided as a kit containing the above-mentioned lubricating layer-forming agent as a second component, which simultaneously includes a crosslinking reactive component constituting a body correcting film and a crosslinking component that crosslinks the crosslinking reactive component. Such a kit may similarly include any of the above-mentioned components.

[0150] Furthermore, in order to prevent contact between the first agent and the second agent (lubricating layer forming agent), such a kit may also contain these agents in separate containers, or in separate containers within each of two or more compartments.

[0151] In one embodiment, the product can be provided as a kit comprising the above-described first agent constituting a coating-type body corrective film-forming agent, a second agent containing or not containing a lubricating component, and the above-described lubricating layer-forming agent as a third agent. Such a kit may similarly include any of the above-described components.

[0152] To prevent contact between the first, second, and third agents, such a kit may contain these agents in separate containers, or in separate containers within each of three or more compartments. Furthermore, the contained first and second agents may be configured to be applied one at a time, or to be mixed together before or during use.

[0153] Body Correction Membrane <Thickness> There are no particular limitations on the thickness of the body correction film prepared using the coating-type body correction film-forming agent of this disclosure described above. For example, it can be adjusted as appropriate considering factors such as breathability, invisibility, compressibility, and occlusion of the skin. The thickness of the body correction film can be, for example, 0.5 μm or more, 1 μm or more, 10 μm or more, 30 μm or more, or 40 μm or more. There are no particular limitations on the upper limit of the thickness, but for example, it can be 150 μm or less, 100 μm or less, 90 μm or less, 80 μm or less, 70 μm or less, 60 μm or less, or 50 μm or less. Here, the thickness can be defined as the average value calculated by measuring the thickness of any part of the body correction film five times using a high-precision digital micrometer (MDH-25MB, manufactured by Mitutoyo Corporation).

[0154] <Performance> Body correction films prepared from the coating-type body correction film-forming agent of this disclosure can yield excellent results in various performance aspects, such as those described below.

[0155] (adhesive strength) In some embodiments, the resulting body correction film can exhibit good adhesion to the body surface. This adhesion can be evaluated by comparing it to the adhesion of the body correction film applied to a polypropylene substrate. The adhesion of the body correction film on a polypropylene substrate can achieve values ​​of 2 N / m or more, 5 N / m or more, 8 N / m or more, 10 N / m or more, or 15 N / m or more. There is no particular upper limit to the adhesion, but for example, from the viewpoint of peelability from the skin, it can be set to 200 N / m or less, 100 N / m or less, 80 N / m or less, 50 N / m or less, or 30 N / m or less. Here, the adhesion can be measured using an Instron device in accordance with the peel adhesion test of ASTM C794.

[0156] (Tensile strength) In some embodiments, the resulting body correction film can exhibit good tensile strength. The tensile strength of the body correction film can achieve 0.05 MPa or higher, 0.10 MPa or higher, 0.20 MPa or higher, or 0.50 MPa or higher. There is no particular upper limit on the tensile strength, but for example, it can be 5.0 MPa or lower, 3.0 MPa or lower, 2.0 MPa or lower, or 1.0 MPa or lower. Here, the tensile strength can be measured using an Instron device in accordance with the elongation tensile test of ASTM D5083.

[0157] (Elongation at break) In some embodiments, the resulting body correction film can exhibit good elongation at break. The elongation at break of the body correction film can be 25% or more, 50% or more, 100% or more, 200% or more, or 400% or more. There is no particular upper limit to the elongation at break, but for example, it can be 1,500% or less, 1,200% or less, 1,000% or less, 800% or less, or 600% or less. Here, the elongation at break can be measured using an Instron device in accordance with the tensile strength test of ASTM D5083.

[0158] (Oxygen permeability) In some embodiments, the resulting body correction film can exhibit good oxygen permeability. The oxygen permeability of the body correction film is 5 × 10⁻¹⁰ for a 300 μm thick body correction film. -9 cm 3 / (cm 2 ·s) or more, 5×10 -7 cm 3 / (cm 2 • s) or more, or 5 x 10 -5 cm 3 / (cm 2 It is possible to achieve a value of 5 cm or higher. There is no particular limit on the upper limit of oxygen permeability, but for example, 5 cm 3 / (cm 2 ·s) or less, 0.5cm 3 / (cm 2 ·s) or less, 5×10 -2 cm 3 / (cm2 ·s) or less, 5×10 -3 cm 3 / (cm 2 ·s) or less, or 5 × 10 -4 cm 3 / (cm 2 ·s) can be less than or equal to the specified value. Here, the oxygen permeability can be measured using a Mocon device in accordance with the oxygen gas permeability test for plastic films and sheets of ASTM F2622.

[0159] (Water vapor transmission rate) In some embodiments, the resulting body correction film can exhibit good water vapor permeability. The water vapor permeability of the body correction film is 1 × 10⁻¹⁶ for a body correction film with a thickness of 300 μm. -9 cm 3 / (cm 2 ·s) or more, 1×10 -8 cm 3 / (cm 2 • s) or more, or 1 × 10 -7 cm 3 / (cm 2 It is possible to achieve a value of 1.5 × 10⁻⁶ or higher. There is no particular upper limit on the water vapor transmission rate, but for example, 1.5 × 10⁻⁶ -1 cm 3 / (cm 2 ·s) or less, 1.5×10 -2 cm 3 / (cm 2 ·s) or less, 1×10 -4 cm 3 / (cm 2 ·s) or less, 1×10 -5 cm 3 / (cm 2 ·s) or less, or 1 × 10 -6 cm 3 / (cm 2 • s) can be less than or equal to the following. Here, the water vapor transmission rate can be measured using a Mocon device in accordance with the water vapor transmission rate test for plastic films and sheets of ASTM F1249. [Examples]

[0160] The present invention will be explained in more detail below with reference to examples, but the present invention is not limited to these examples. Unless otherwise specified, the amounts of the ingredients are expressed in mass percent.

[0161] Evaluation Test The following tests were conducted using each test sample obtained by the manufacturing method described below, and the results are summarized in Tables 1 to 12.

[0162] <Visual inspection of the coating: Durability and protective performance of the coating on the surface> Under conditions of 25℃±1℃ and relative humidity of 50%±2%, approximately 0.1g of the first agent was spread on the forearm to form a roughly circular layer of the first agent with a diameter of approximately 4cm. Then, approximately 0.1g of the second agent was applied to the first agent layer with a finger and spread in a circular motion with the finger to create a body correction film. In the test where a lubricating layer-forming agent was used, approximately 0.1g of the lubricating layer-forming agent was spread onto the body correction film with a finger.

[0163] The obtained coating was visually inspected 12 hours after its preparation for any defects such as peeling or damage, and its durability and protective performance on the surface were evaluated according to the following evaluation criteria. In the evaluation criteria below, A to B ratings are considered passing grades, and C ratings are considered failing grades: A: There was no peeling or damage to the coating. B: There was slight peeling or damage to the coating. C: The coating was clearly peeling or damaged.

[0164] <Abrasion Resistance Test 1: Durability and Protective Performance of the Coating> Approximately 0.1 g of the first agent was spread on the surface of a 3 cm x 10 cm artificial skin (Supplere (trademark): manufactured by Idemitsu Technofine Co., Ltd.) to form a roughly circular first agent layer with a diameter of approximately 4 cm. Then, approximately 0.1 g of the second agent was applied to the first agent layer with a finger, and the second agent was spread in a circular motion with the finger to create a body correction film. In the test where a lubricating layer-forming agent was used, approximately 0.1 g of the lubricating layer-forming agent was spread onto the body correction film with a finger.

[0165] Artificial skin coated with a protective film was placed in a Crock meter (manufactured by Hanchen), and the film was repeatedly rubbed while a load of 1N was applied. The number of rubs until damage to the film occurred was measured. In the evaluation criteria below, grades A through C are considered pass, and grade D is considered fail. The number of rubs until damage is indicated in parentheses in the table: A: The number of times the coating was damaged was 20 or more. B: The number of times the coating was damaged was between 10 and 19. C: The number of times the coating was damaged was between 5 and 9. D: The number of times the coating was damaged was four or less.

[0166] <Abrasion Resistance Test 2: Durability and Protective Performance of the Coating After Makeup> Approximately 0.1 g of the first agent was spread on the surface of a 3 cm x 10 cm artificial skin (Supplere (trademark): manufactured by Idemitsu Technofine Co., Ltd.) to form a roughly circular layer of the first agent with a diameter of approximately 4 cm. Then, approximately 0.1 g of the second agent was applied to the first agent layer with a finger, and the second agent was spread in a circular motion with the finger to create a body correction film. Next, a makeup cosmetic (Synchro Skin Self-Refreshing Foundation SPF 30, manufactured by Shiseido Co., Ltd.) was spread over the body correction film with a finger.

[0167] Artificial skin coated with a protective film was placed in a Crock meter (manufactured by Hanchen), and the film was repeatedly rubbed while a load of 1N was applied. The number of rubs until damage to the film occurred was measured. In the evaluation criteria below, grades A through C are considered pass, and grade D is considered fail. The number of rubs until damage is indicated in parentheses in the table: A: The number of times the coating was damaged was 20 or more. B: The number of times the coating was damaged was between 10 and 19. C: The number of times the coating was damaged was between 5 and 9. D: The number of times the coating was damaged was four or less.

[0168] <Slipperiness and protectiveness test: Slipperiness and protectiveness of the coating to cosmetics> Under conditions of 25℃±1℃ and relative humidity of 50%±2%, approximately 0.1g of the first agent was spread on the forearm to form a roughly circular layer of the first agent with a diameter of approximately 4cm. Then, approximately 0.1g of the second agent was applied to the first agent layer with a finger, and the second agent was spread in a circular motion with the finger to create a body correction film. In the test where a lubricating layer-forming agent was used, approximately 0.1g of the lubricating layer-forming agent was spread onto the body correction film with a finger.

[0169] A foundation containing inorganic powder (Synchro Skin Self-Refreshing Foundation SPF 30, manufactured by Shiseido Co., Ltd.) was applied to the resulting film using a finger. The film was visually inspected for any defects such as peeling or damage, and the uniformity or unevenness of the foundation application was also visually inspected. The film's slipperiness and protective properties against cosmetics were then evaluated according to the following criteria. In the following evaluation criteria, an A rating is considered a pass, while B and C ratings are considered a fail: A: There was no peeling or damage to the film, and the foundation was applied evenly. B: There was no peeling or damage to the film, but the foundation application was uneven. C: The coating peeled or was damaged, and the foundation applied unevenly.

[0170] [Test Example 1: Effect of Lubricating Components on Film When Using a Second Agent in an Oil-in-Water Formulation] In Test Example 1, the effect of the lubricating component on the protective performance against external stimuli on the film when using an oil-in-water formulation of the second agent was investigated. The results are shown in Table 1.

[0171] <First Agent> The first agent was prepared by uniformly mixing 41 parts by mass of 165,000 cst divinyldimethicone as the first unsaturated organopolysiloxane, 9 parts by mass of 45 cst hydrogendimethicone as the first hydride-functionalized polysiloxane, 7 parts by mass of silylated silica as a filler, and 43 parts by mass of a mixture of dimethicone and trisiloxane as an oil component.

[0172] <Second drug> The second component of the oil-in-water composition was prepared using the formulation shown in Table 1 by the following method. Here, the numbers shown below correspond to the numbers indicating the left-hand components of the formulation in Table 1.

[0173] (Comparative Example 1) Materials No. 1 and No. 7 to No. 9 were uniformly mixed to prepare an aqueous phase component. Then, catalyst No. 5 was added to this aqueous phase component and uniformly mixed to prepare the second component of the oil-in-water type non-emulsified composition of Comparative Example 1.

[0174] (Example 1) Materials No. 1, No. 3, and No. 4, as well as No. 6 to No. 9, were uniformly mixed to prepare an aqueous phase component. Then, catalyst No. 5 was added to this aqueous phase component and uniformly mixed to prepare the second component of the oil-in-water emulsion composition of Example 1.

[0175] (Examples 2-7) The second component of the oil-in-water emulsion compositions of Examples 2-7 was prepared in the same manner as in Example 1, except that the formulation was changed to that shown in Table 1. The lubricating component No. 2 was added during the preparation of the aqueous phase parts.

[0176] [Table 1]

[0177] <result> The results in Table 1 confirm that the inclusion of a lubricating component in the oil-in-water type second agent improves the protective performance of the coating against external stimuli.

[0178] Furthermore, a comparison of Examples 2 to 7 revealed that when the amount of glycerin, a humectant with a sugar backbone, is 4.5% by mass or more, the slipperiness and protective properties of the film against cosmetics are improved.

[0179] [Test Example 2: Effect of the type and amount of humectant with a sugar skeleton on the film in an oil-in-water type second agent] In Test Example 2, the effects of the type and amount of humectant containing a sugar skeleton in the oil-in-water type second agent on the protective performance of the film against external stimuli were investigated. The results are shown in Table 2.

[0180] <First Agent> The first agent was prepared by uniformly mixing 30 parts by mass of 165,000 cst divinyldimethicone as the first unsaturated organopolysiloxane, 7 parts by mass of 45 cst hydrogendimethicone as the first hydride-functionalized polysiloxane, 6 parts by mass of silylated silica as a filler, and 57 parts by mass of a mixture of dimethicone and trisiloxane as an oil component.

[0181] <Second drug> The second component of the oil-in-water composition was prepared using the formulations shown in Table 2 by the following method. Here, the numbers shown below correspond to the numbers indicating the left-hand components of the formulations in Table 2.

[0182] (Comparative Example 2) Materials No. 1 and No. 10 to No. 12 were uniformly mixed to prepare an aqueous phase component. Then, catalyst No. 8 was added to this aqueous phase component and uniformly mixed to prepare the second component of the oil-in-water type non-emulsified composition of Comparative Example 2.

[0183] (Example 8) Materials No. 1, No. 2, No. 6, No. 7, and No. 10 to No. 12 were uniformly mixed to prepare an aqueous phase component. Then, catalyst No. 8 was added to this aqueous phase component and uniformly mixed to prepare the second component of the oil-in-water emulsion composition of Example 8.

[0184] (Examples 9-15) Except for changing the formulation in Table 2, the second agent of the oil-in-water emulsion compositions of Examples 9 to 15 was prepared in the same manner as in Example 8. The material of No. 9 was blended during the preparation of the aqueous phase parts.

[0185]

Table 2

[0186] 〈Results〉 From the results in Table 2, it was confirmed that in any case, the humectant having a sugar skeleton improved the protective performance of the film against external stimuli.

[0187] Also, it was found that when the blending amount of the humectant having a sugar skeleton increased, in any case, the abrasion resistance and the slipperiness and protectiveness of the film against cosmetics improved.

[0188] 《Test Example 3: Influence of the film-forming agent on the film in the second agent of the oil-in-water type》 In Test Example 2, the influence of the film-forming agent in the second agent of the oil-in-water type on the protective performance against external stimuli of the film was examined. The results are shown in Table 3.

[0189] 〈First agent〉 45 parts by mass of divinyldimethylsilicone with a viscosity of 165,000 cst as the first unsaturated organopolysiloxane, 10 parts by mass of hydrogen dimethylsilicone with a viscosity of 45 cst as the first hydride-functionalized polysiloxane, 7.5 parts by mass of silylated silica as a filler, and 37.5 parts by mass of a mixture of (crotonic acid / vinyl isoalkyl (C8-12) esters / VA / bisvinyl dimethylsilicone) cross polymer and denatured alcohol as an oil component were uniformly mixed to prepare the first agent.

[0190] 〈Second agent〉 Using the formulation shown in Table 3, the second agent of the oil-in-water composition was produced by the following method. Here, the numbers shown below correspond to the numbers of the components on the left side of the formulation in Table 3.

[0191] (Example 16) The aqueous phase parts were prepared by uniformly mixing materials No. 1, No. 2, No. 4, No. 6, No. 7, No. 9, No. 10, and No. 14.

[0192] The oil phase parts were prepared by uniformly mixing materials No. 3, No. 5, and No. 8.

[0193] The oil phase component was added to the aqueous phase component and mixed uniformly to prepare the second component of the oil-in-water emulsion composition of Example 16.

[0194] (Examples 17-19) The second components of the oil-in-water emulsion compositions of Examples 17-19 were prepared in the same manner as in Example 16, except that the formulation was changed to that shown in Table 3. The lubricating components No. 11-13 were added during the preparation of the aqueous phase parts.

[0195] [Table 3]

[0196] <result> The results in Table 3 confirm that incorporating a coating agent further improves the protective performance of the coating against external stimuli.

[0197] [Test Example 4: Effect of Lubricating Components on the Film When Using a Water-in-Oil Type Second Agent] In Test Example 4, the effect of the lubricating component on the protective performance against external stimuli on the film when using a water-in-oil formulation of the second agent was investigated. The results are shown in Table 4.

[0198] <First Agent> The first agent was prepared by uniformly mixing 50 parts by mass of 165,000 cst divinyldimethicone as the first unsaturated organopolysiloxane, 11 parts by mass of 45 cst hydrogendimethicone as the first hydride-functionalized polysiloxane, 8 parts by mass of silylated silica as a filler, and 31 parts by mass of a mixture of dimethicone and trisiloxane as an oil component.

[0199] <Second Agent> Using the formulation shown in Table 4, the second agent of the water-in-oil composition was produced by the following method. Here, the numbers shown below correspond to the numbers of the components on the left side of the formulation in Table 4.

[0200] (Comparative Example 3) The materials of No. 1 to No. 5 and No. 8 were uniformly mixed to prepare the oil-phase parts.

[0201] The materials of No. 6, No. 7, No. 9 to No. 11 were uniformly mixed to prepare the water-phase parts.

[0202] The water-phase parts were added to the oil-phase parts and uniformly mixed to prepare the second agent of the water-in-oil emulsion composition of Comparative Example 3.

[0203] (Examples 20 to 26) Except for changing the formulation in Table 4, the second agents of the water-in-oil emulsion compositions of Examples 20 to 26 were prepared in the same manner as in Comparative Example 3. The materials of No. 12, No. 14 to No. 16 were incorporated during the preparation of the water-phase parts, and the material of No. 13 was incorporated during the preparation of the oil-phase parts.

[0204] [Table 4]

[0205] <Results> From the results in Table 4, it was confirmed that in the water-in-oil second agent, when a lubricity component is contained, the protection performance against external stimuli of the film, as well as the slipperiness and protectiveness of the film against cosmetics, are improved.

[0206] <<Test Example 5: Influence on Film by Types of Lubricity Components in Water-in-Oil Second Agent>> In Test Example 5, the influence of the types of lubricity components in the water-in-oil second agent on the protection performance against external stimuli of the film and the like was examined. The results are shown in Table 5.

[0207] <First Agent> The first agent was prepared by uniformly mixing 45 parts by mass of 165,000 cst divinyldimethicone as the first unsaturated organopolysiloxane, 10 parts by mass of 50 cst hydrogendimethicone, 7.5 parts by mass of graphene, 10 parts by mass of zinc oxide as the first hydride-functionalized polysiloxane, and 27.5 parts by mass of 1.5 cst dimethicone as the oil component.

[0208] <Second drug> The second component of the water-in-oil composition was prepared using the formulation shown in Table 5 by the following method. Here, the numbers shown below correspond to the numbers indicating the left-hand components of the formulation in Table 5.

[0209] (Comparative Example 4) The oil phase parts were prepared by uniformly mixing materials No. 1 to No. 4 and No. 6.

[0210] Materials No. 5, No. 7, and No. 12 were uniformly mixed to prepare the aqueous phase components.

[0211] The aqueous phase component was added to the oil phase component and uniformly mixed to prepare the second component of the water-in-oil emulsion composition of Comparative Example 4.

[0212] (Examples 27-31) The second components of the water-in-oil emulsion compositions of Examples 27-31 were prepared in the same manner as in Comparative Example 4, except for the change in formulation shown in Table 5. Materials No. 10 and No. 11 were added during the preparation of the aqueous phase component, and materials No. 8 and No. 9 were added during the preparation of the oil phase component.

[0213] [Table 5]

[0214] <result> The results in Table 5 show that, in the second agent, using the lubricating component alone or in combination improved the protective performance of the film against external stimuli, as well as the slipperiness and protective properties of the film against cosmetics.

[0215] Test Example 6: Effect of Lubricating Components on the Film When Using a Second Agent in an Oil-Phase Single-Phase System In Test Example 6, the effect of the lubricating component on the protective performance of the film against external stimuli when using a single-phase oil-based formulation of the second agent was investigated. The results are shown in Table 6.

[0216] <First Agent> The first agent was prepared by uniformly mixing 42 parts by mass of 165,000 cst divinyldimethicone as the first unsaturated organopolysiloxane, 10 parts by mass of 50 cst hydrogendimethicone and 10 parts by mass of graphene as the first hydride-functionalized polysiloxane, and 38 parts by mass of 1.5 cst dimethicone as the oil component.

[0217] <Second drug> Using the formulations shown in Table 6, each component was uniformly mixed to prepare the oil-phase single-phase second agent for Comparative Example 5 and Examples 32-34.

[0218] [Table 6]

[0219] <result> The results in Table 6 confirm that the inclusion of a lubricating component in the oil-phase single-phase second agent improves the protective performance of the film from external stimuli, as well as the slipperiness and protective properties of the film against cosmetic products.

[0220] 《Test Example 7: Effect of Lubricant Amount in a Single-Phase Oil-Phase Second Agent on the Film》 In Test Example 7, the effect of the amount of lubricating component in the second agent of a single-phase oil system on the protective performance of the film from external stimuli was investigated. The results are shown in Table 7.

[0221] <First Agent> The first agent was prepared by uniformly mixing 20 parts by mass of 165,000 cst divinyldimethicone as the first unsaturated organopolysiloxane, 5 parts by mass of 45 cst hydrogen dimethicone as the first hydride-functionalized polysiloxane, 1 part by mass of a mixture of PEG-10 dimethicone and tocopherol as an emulsifier, 40 parts by mass of ion-exchanged water, 1 part by mass of sodium chloride, 1 part by mass of 1,3-butylene glycol, 0.5 parts by mass of phenoxyethanol, and 31.5 parts by mass of a mixture of dimethicone and trisiloxane as an oil component.

[0222] <Second drug> Using the formulations shown in Table 7, the components were uniformly mixed to prepare the oil-phase single-phase second agent for Examples 35-37.

[0223] [Table 7]

[0224] <result> The results in Table 7 confirm that when the oil-phase single-phase second agent contains more than 5.0% by mass of lubricating components, the protective performance of the film from external stimuli, as well as the slipperiness and protective properties of the film relative to cosmetics, are further improved.

[0225] [Test Example 8: Effect of Lubricating Components on Film When Using the Second Agent of a Non-Emulsified Two-Phase Dosage Form] In Test Example 8, the effect of the lubricating component on the protective performance against external stimuli on the film when using the second component of a non-emulsified two-phase formulation was investigated. The results are shown in Table 8.

[0226] <First Agent> The first agent was prepared by uniformly mixing 45 parts by mass of 165,000 cst divinyldimethicone as the first unsaturated organopolysiloxane, 10 parts by mass of 45 cst hydrogendimethicone as the first hydride-functionalized polysiloxane, 7.5 parts by mass of silylated silica as a filler, and 37.5 parts by mass of a mixture of (crotonic acid / vinyl isoalkyl (C8-12) esters / VA / bisvinyldimethicone) crosspolymer and modified alcohol as an oil component.

[0227] <Second drug> Using the formulations shown in Table 8, the components were uniformly mixed to prepare the second non-emulsified two-phase system of Examples 38-40.

[0228] [Table 8]

[0229] <result> The results in Table 8 confirm that the inclusion of a lubricating component in the second agent of the non-emulsified two-phase system improves the protective performance of the film from external stimuli, as well as the slipperiness and protective properties of the film against cosmetics.

[0230] Furthermore, it was confirmed that when the second component of a non-emulsified two-phase system contains more than 5.0% by mass of a lubricating component, the protective performance of the film from external stimuli, as well as the slipperiness and protective properties of the film relative to cosmetics, are further improved.

[0231] Test Example 9: Effect on the coating when a lubricating component is added to the first agent. In Test Example 9, the effect of incorporating a lubricating component into the first agent on the protective performance of the coating against external stimuli was investigated. The results are shown in Table 9.

[0232] <First Agent> The first component of the water-in-oil emulsion composition was prepared using the formulation shown in Table 9 by the following method. Here, the numbers shown below correspond to the numbers indicating the left-hand components of the formulation in Table 9.

[0233] (Comparative Example 6) The aqueous phase parts were prepared by uniformly mixing materials No. 3 to No. 6 and No. 11.

[0234] The oil phase parts were prepared by uniformly mixing materials No. 1, No. 2, and No. 12.

[0235] The first component of the water-in-oil emulsion composition of Comparative Example 6 was prepared by adding the aqueous phase component to the oil phase component and mixing them uniformly.

[0236] (Comparative Examples 7-11) The first component of the water-in-oil compositions of Comparative Examples 7 to 11 was prepared in the same manner as Comparative Example 6, except for the change in formulation shown in Table 9. Materials No. 7 and No. 9 to No. 11 were added during the preparation of the aqueous phase component, while material No. 8 was added during the preparation of the oil phase component.

[0237] <Second drug> The second agent, which does not contain a lubricating component, was used, as per the formulation of Comparative Example 4 in Table 5.

[0238] [Table 9]

[0239] <result> The results in Table 9 show that when a lubricating component is added to the first agent, the protective performance of the film from external stimuli, as well as the slipperiness and protective properties of the film against cosmetics, do not improve; on the contrary, these performances decrease.

[0240] Test Example 10: Effects on the coating when using a lubricating layer-forming agent (third agent) containing a water-soluble polymer as a lubricating component. In Test Example 10, the effect of using a lubricating layer-forming agent (third agent) containing a water-soluble polymer as a lubricating component on the protective performance of the coating against external stimuli was investigated. The results are shown in Table 10.

[0241] <First Agent> The first agent was prepared by uniformly mixing 45 parts by mass of 165,000 cst divinyldimethicone as the first unsaturated organopolysiloxane, 10 parts by mass of 45 cst hydrogendimethicone as the first hydride-functionalized polysiloxane, 7.5 parts by mass of silylated silica as a filler, and 37.5 parts by mass of a mixture of (crotonic acid / vinyl isoalkyl (C8-12) esters / VA / bisvinyldimethicone) crosspolymer and modified alcohol as an oil component.

[0242] <Second drug> The second agent, which does not contain a lubricating component, was used, as per the formulation of Comparative Example 1 in Table 1.

[0243] <Third agent: Lubrication layer forming agent> Using the formulations shown in Table 10, the third component of the aqueous single-phase system for Comparative Example 12 and Examples 41-46 was prepared by uniformly mixing each component.

[0244] [Table 10]

[0245] <result> The results in Table 10 confirm that when a water-soluble polymer is included as a lubricating component in the third agent, the protective performance of the film from external stimuli, as well as the slipperiness and protective properties of the film against cosmetics, are improved.

[0246] Test Example 11: Effects on the coating when using a lubricating layer-forming agent (third agent) containing a humectant with a sugar skeleton as a lubricating component. In Test Example 11, the effects of using a lubricating layer-forming agent (third agent) containing a humectant with a sugar skeleton as a lubricating component on the protective performance of the coating against external stimuli were investigated. The results are shown in Table 11.

[0247] <First Agent> The first agent was prepared by uniformly mixing 50 parts by mass of 165,000 cst divinyldimethicone as the first unsaturated organopolysiloxane, 11 parts by mass of 45 cst hydrogendimethicone as the first hydride-functionalized polysiloxane, 8 parts by mass of silylated silica as a filler, and 31 parts by mass of a mixture of dimethicone and trisiloxane as an oil component.

[0248] <Second drug> The second agent, which does not contain a lubricating component, was used, as per the formulation of Comparative Example 4 in Table 5.

[0249] <Third agent: Lubrication layer forming agent> Using the formulations shown in Table 11, the third component of the aqueous single-phase system used in Examples 47-57 was prepared by uniformly mixing each component.

[0250] [Table 11]

[0251] <result> The third agents of Examples 47 and 48 also contain a water-soluble polymer as a lubricating component, improving the protective performance of the film from external stimuli, as well as the slipperiness and protective properties of the film against cosmetics. However, it was found that the third agents of Examples 49 to 57, which further contain a humectant with a sugar skeleton, show even greater improvements in these performances.

[0252] Furthermore, a comparison of Examples 49 and 50 revealed that when the amount of humectant containing a sugar skeleton is 4.5% by mass or more, the protective performance of the film from external stimuli is further improved.

[0253] Test Example 12: Effects on the coating when using a lubricating layer-forming agent (third agent) containing a film-forming agent as a lubricating component. In Test Example 12, the effects of using a lubricating layer-forming agent (third agent) containing a film-forming agent as a lubricating component on the protective performance of the coating from external stimuli were investigated. The results are shown in Table 12.

[0254] <First Agent> The first agent was prepared by uniformly mixing 25 parts by mass of 165,000 cst divinyldimethicone as the first unsaturated organopolysiloxane, 10 parts by mass of 45 cst hydrogen dimethicone as the first hydride-functionalized polysiloxane, 1 part by mass of a mixture of PEG-10 dimethicone and tocopherol as an emulsifier, 40 parts by mass of ion-exchanged water, 1 part by mass of sodium chloride, 1 part by mass of 1,3-butylene glycol, 0.5 parts by mass of phenoxyethanol, and 21.5 parts by mass of a mixture of dimethicone and trisiloxane as an oil component.

[0255] <Second drug> One part by mass of sodium chloride, ten parts by mass of denatured alcohol, ten parts by mass of 1,3-butylene glycol, 0.5 parts by mass of phenoxyethanol, ten parts by mass of a mixture of dimethicone and trisiloxane, five parts by mass of vinyl dimethicone, five parts by mass of isododecane, and two parts by mass of a mixture of vinyl dimethicone, divinyldisiloxane, and a platinum catalyst were added to deionized water to a total of 100 parts by mass, and the mixture was homogenized to prepare a non-emulsified two-phase second agent.

[0256] <Third agent: Lubrication layer forming agent> Using the formulations shown in Table 12, the third component of the aqueous single-phase system used in Examples 58-65 was prepared by uniformly mixing each component.

[0257] [Table 12]

[0258] <result> The results in Table 12 confirm that when a coating agent is included as a lubricating component in the third agent, the protective performance of the coating against external stimuli, as well as the slipperiness and protective properties of the coating against cosmetics, are improved.

[0259] Examples of prescriptions for topical body correction film-forming agents. The following are examples of formulations for the first, second, and third agents (lubricating layer forming agents) that can be used as the coating-type body corrective film-forming agents of this disclosure, but the coating-type body corrective film-forming agents of the present invention are not limited to these examples. All of the coating-type body corrective film-forming agents described in the following formulation examples exhibited excellent protective performance against external stimuli to the film. The above-mentioned tests were also conducted for the formulation examples shown below, and the results are summarized in Tables 13 to 21. Here, in the abrasion resistance test, if the number of cycles until damage to the film occurred exceeded 100, it is indicated as "100<".

[0260] <Prescription Example A> (First drug) The first agent was prepared by uniformly mixing 25 parts by mass of 165,000 cst divinyldimethicone as the first unsaturated organopolysiloxane, 10 parts by mass of 45 cst hydrogen dimethicone as the first hydride-functionalized polysiloxane, 1 part by mass of a mixture of PEG-10 dimethicone and tocopherol as an emulsifier, 40 parts by mass of ion-exchanged water, 1 part by mass of sodium chloride, 1 part by mass of 1,3-butylene glycol, 0.5 parts by mass of phenoxyethanol, and 21.5 parts by mass of a mixture of dimethicone and trisiloxane as an oil component.

[0261] (Second drug) Using the formulations shown in Table 13, the second component of the oil-in-water emulsion composition was prepared by the following method. Here, the numbers shown below correspond to the numbers indicating the left-hand components of the formulations in Table 13.

[0262] a. Prescription example 1 The aqueous phase parts were prepared by uniformly mixing materials No. 1, No. 2, No. 7 to No. 11, and No. 13 to No. 15.

[0263] The oil phase parts were prepared by uniformly mixing materials No. 3, No. 9, and No. 12.

[0264] The oil phase component was added to the aqueous phase component and mixed uniformly to prepare the second component of the oil-in-water emulsion composition of Formulation Example 1.

[0265] b. Prescription Examples 2-5 Except for the changes to the formulations shown in Table 13, the second components of the oil-in-water emulsion compositions for Formulation Examples 2-5 were prepared in the same manner as Formulation Example 1. Materials No. 3-6 were added during the preparation of the aqueous phase components.

[0266] [Table 13]

[0267] <Prescription Example B> (First drug) The first agent was prepared by uniformly mixing 45 parts by mass of 165,000 cst divinyldimethicone as the first unsaturated organopolysiloxane, 10 parts by mass of 50 cst hydrogendimethicone, 7.5 parts by mass of graphene, 10 parts by mass of iron oxide as the first hydride-functionalized polysiloxane, and 27.5 parts by mass of 1.5 cst dimethicone as the oil component.

[0268] (Second drug) Using the formulations shown in Table 14, the second component of the water-in-oil emulsion composition was prepared by the following method. Here, the numbers shown below correspond to the numbers indicating the left-hand components of the formulations in Table 14.

[0269] a. Prescription example 6 The oil phase parts were prepared by uniformly mixing materials No. 1 to No. 4, No. 6, No. 8, and No. 10.

[0270] The aqueous phase parts were prepared by uniformly mixing materials No. 5, No. 7, No. 9, and No. 11-13.

[0271] The aqueous phase component was added to the oil phase component and mixed uniformly to prepare the second component of the water-in-oil emulsion composition of Formulation Example 6.

[0272] b. Prescription Examples 7-9 The second component of the water-in-oil emulsion compositions of formulations 7-9 was prepared in the same manner as formulation example 6, except for the change in formulation shown in Table 14. Note that material No. 12 was added during the preparation of the aqueous phase component.

[0273] [Table 14]

[0274] <Prescription Example C> (First drug) The first agent of the formulation in Comparative Example 8 in Table 9 was used.

[0275] (Second drug) The second drug in prescription example 3 of Table 13 was used.

[0276] (Third agent: Lubricating layer forming agent) Using the formulations shown in Table 15, the third component of the aqueous single-phase system for formulations 10-12 was prepared by uniformly mixing each component.

[0277] [Table 15]

[0278] <Prescription Example D> (First drug) The first agent of the formulation in Comparative Example 11 in Table 9 was used.

[0279] (Second drug) The second formulation of Comparative Example 2 in Table 2 was used.

[0280] (Third agent: Lubricating layer forming agent) a. Prescription example 13 The aqueous phase parts were prepared by uniformly mixing materials No. 1 to No. 6, No. 8, No. 9, and No. 11 to No. 13.

[0281] Materials No. 7 and No. 10 were uniformly mixed to prepare the oil phase parts.

[0282] The oil phase component was added to the aqueous phase component and uniformly mixed to prepare the third component of the oil-in-water emulsion composition of Formulation Example 13.

[0283] b. Prescription Examples 14-15 The third component of the oil-in-water emulsion composition for formulations 14-15 was prepared in the same manner as formulation example 13, except that the formulation was changed to that shown in Table 16.

[0284] [Table 16]

[0285] <Prescription Example E> (First drug) The first agent was prepared by uniformly mixing 45 parts by mass of 165,000 cst divinyldimethicone as the first unsaturated organopolysiloxane, 10 parts by mass of 50 cst hydrogendimethicone, 7.5 parts by mass of graphene, 10 parts by mass of titanium dioxide as the first hydride-functionalized polysiloxane, and 27.5 parts by mass of 1.5 cst dimethicone as the oil component.

[0286] (Second drug) The second agent of the formulation in Example 20 of Table 4 was used.

[0287] (Third agent: Lubricating layer forming agent) a. Prescription example 16 The oil phase parts were prepared by uniformly mixing materials No. 1 to No. 5 and No. 8.

[0288] The aqueous phase parts were prepared by uniformly mixing materials No. 6, No. 7, No. 9, No. 10, and No. 14.

[0289] The aqueous phase component was added to the oil phase component and uniformly mixed to prepare the third component of the water-in-oil emulsion composition of Formulation Example 16.

[0290] b. Prescription Examples 17-19 The third component of the water-in-oil emulsion compositions of formulations 17-19 was prepared in the same manner as formulation example 16, except for the change in formulation shown in Table 17. Materials No. 11 and No. 12 were added during the preparation of the oil phase component, and material No. 13 was added during the preparation of the aqueous phase component.

[0291] [Table 17]

[0292] [Example of a prescription for the first agent of a topical body correction film-forming agent] Tables 18 to 21 show examples of formulations of the first agent that can be used as a topical body corrective film-forming agent according to this disclosure, but the first agent of the topical body corrective film-forming agent of the present invention is not limited to these examples. These formulations can be prepared by conventional methods.

[0293] [Table 18]

[0294] [Table 19]

[0295] [Table 20]

[0296] [Table 21]

Claims

[Claim 1] A second agent of a coating-type body corrective film-forming agent, comprising a first agent containing a crosslinking reactive component that constitutes a body corrective film, and a second agent containing a crosslinking component that crosslinks the crosslinking reactive component, The aforementioned crosslinking component includes a catalyst and a lubricating component. Second drug.

Images